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ABSTRACT 
   
SEVERELY STRESSED ASTROCYTES ADAPT TO INJURY AND STILL PROTECT 
NEIGHBORING NEURONS 
 
 
 
By 
Amanda Marie Gleixner 
December 2015 
 
Dissertation supervised by Rehana K. Leak 
Neurodegenerative disorders such as Parkinson’s and Alzheimer’s disease are projected 
to affect 15.14 million people by the year 2050. All neurodegenerative diseases are characterized 
by protein-misfolding stress, or proteotoxicity, in both neurons and glia. However, the impact of 
proteotoxicity on glia is less well understood than in neurons. Astrocytes are an abundant type of 
glia and play an essential role in brain homeostasis by supporting neuronal functions. Therefore, 
one of the major goals of the present study was to identify ways to reduce the impact of 
proteotoxicity in astrocytes. In Aim 1, we examined natural adaptations to proteotoxic stress in 
astrocytes. Our studies demonstrate that the astrocytes surviving a severe proteotoxic insult are 
resistant to subsequent challenges due to upregulation of the antioxidant biomolecule 
glutathione. Prior to this body of work, only mild stressors were thought to elicit stress tolerance 
and severe stress was thought to only weaken cells. In contrast with traditional views of reactive 
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astrocytes, severely stressed astrocytes were still able to protect neighboring neurons from 
proteotoxic injury in our model. In Aim 2, we examined the therapeutic potential of N-acetyl 
cysteine, a glutathione precursor known to benefit patients with neurological disorders. We 
discovered that N-acetyl cysteine protected astrocytes from proteotoxic stress independent of 
glutathione. Instead, the protection afforded by N-acetyl cysteine was abolished by heat shock 
protein inhibitors, suggesting a novel mechanism of action for N-acetyl cysteine in astrocytes. It 
is important to promote heat shock protein activity in patients with neurodegenerative conditions 
because loss of chaperone defenses may contribute to proteotoxicity in the elderly. In Aim 3, we 
characterized the impact of aging on the expression of several heat shock proteins, many of 
which are expressed in astrocytes. We discovered age-related changes in multiple heat shock 
proteins in the substantia nigra, caudoputamen, and olfactory bulb, three regions known to 
develop Lewy pathology in Parkinson’s disease. In conclusion, astrocytes can be protected 
against protein-misfolding stress by upregulation of endogenous glutathione defenses or by N-
acetyl cysteine treatment. Furthermore, some heat shock proteins are increased with aging, 
perhaps as an endogenous defense against proteotoxic stress in older animals. 
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Chapter 1 Introduction 
1.1 Neurodegenerative diseases 
Alzheimer’s and Parkinson’s disease are the most prevalent neurodegenerative disorders 
and are becoming increasingly common as the United States’ population ages (Hebert, Weuve, 
Scherr, & Evans, 2013; Kowal, Dall, Chakrabarti, Storm, & Jain, 2013). Patients with 
Parkinson’s disease exhibit premotor (hyposmia, rapid eye movement disturbances), motor 
(rigidity, resting tremor, dyskinesia), and nonmotor (depression, anxiety, psychosis) symptoms, 
although the motor symptoms are the most easily recognized (Chaudhuri, Healy, & Schapira, 
2006; Ponsen et al., 2004). Alzheimer’s patients exhibit memory loss, personality changes, and 
cognitive impairments (Mega, Cummings, Fiorello, & Gornbein, 1996). The etiologies of 
Parkinson’s and Alzheimer’s disease have not been established but are attributed to a 
combination of genetic and environmental factors (Gatz et al., 2006; Warner & Schapira, 2003). 
For example, residence in rural areas and chronic exposure to pesticides and herbicides are 
known to increase the risk for developing Parkinson’s disease (McCormack et al., 2002). 
Parkinson’s disease is more prevalent in men whereas women are at greater risk for developing 
Alzheimer’s disease (Fratiglioni et al., 1997; Van Den Eeden et al., 2003). Both disorders place 
an enormous physical and emotional toll on patients and their caregivers. It is estimated that 
greater than 240 billion dollars are spent annually on caring for patients with these two 
conditions (M. D. Hurd, Martorell, & Langa, 2013; Kowal, et al., 2013). Thus, it is imperative to 
find treatments that will slow or halt the progression of these disorders.  
1.1.1 Hallmark pathologies in Parkinson’s and Alzheimer’s disease 
All neurodegenerative diseases are characterized by progressive cell loss in specific brain 
regions over the course of years, if not decades. Vulnerable brain regions in these conditions are 
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known to exhibit high levels of oxidative stress in postmortem analyses (Jenner, Dexter, Sian, 
Schapira, & Marsden, 1992; Markesbery, 1997). For example, the hippocampus and cortex 
exhibit increases in advanced glycation end productions, nitration, lipid peroxidation adduction, 
and carbonyl-modified neurofilament proteins in Alzheimer’s patients (Adams, Klaidman, 
Odunze, Shen, & Miller, 1991; Venkateshappa, Harish, Mahadevan, Srinivas Bharath, & 
Shankar, 2012; Venkateshappa et al., 2012). In response to oxidative damage, numerous 
compensatory changes in pro-survival molecules, such as glutathione, are also evident in these 
disorders (Damier, Hirsch, Zhang, Agid, & Javoy-Agid, 1993; Mythri et al., 2011). Furthermore, 
other antioxidant defense systems, such as heme oxygenase 1 (heat shock protein 32 (Hsp32) or 
HO1) and superoxide dismutases are increased in neurodegenerative diseases (Jenner, 1992; 
Mateo et al., 2010). The upregulation of endogenous antioxidant defenses may at least partly 
explain the slow progression of neurodegeneration in these conditions. Thus, enhancing these 
cellular defenses through pharmacological methods may further delay the progression of 
neurodegenerative diseases. 
Besides evidence of oxidative stress, another major hallmark of neurodegenerative 
conditions is the stereotyped, progressive accumulation of protein aggregations in specific brain 
regions (Braak, Ghebremedhin, Rub, Bratzke, & Del Tredici, 2004; Braak, Rub, Gai, & Del 
Tredici, 2003; Braak, Rub, Schultz, & Del Tredici, 2006; Braak, Sastre, & Del Tredici, 2007). 
For example, Parkinson’s patients exhibit alpha-synuclein+ Lewy bodies and Lewy neurites and 
Alzheimer’s patients exhibit extracellular beta-amyloid plaques and intracellular neurofibrillary 
tangles containing hyperphosphorylated tau (Hardy & Selkoe, 2002; Spillantini, Crowther, Jakes, 
Hasegawa, & Goedert, 1998). The buildup of misfolded proteins in both conditions is thought to 
inhibit the activity of the proteasomal and lysosomal protein degradation systems (Keller, Hanni, 
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& Markesbery, 2000a; McNaught, Belizaire, Isacson, Jenner, & Olanow, 2003; McNaught & 
Jenner, 2001). Thus, both Parkinson’s and Alzheimer’s disease are characterized by severe and 
inexorable loss of protein homeostasis. This loss of protein homeostasis is also known as 
proteotoxicity and is thought to propel and propagate oxidative stress (Alexandrova, Petrov, 
Georgieva, Kirkova, & Kukan, 2008a; Morimoto, 2008). Conversely, reactive oxygen species 
can oxidize proteins, disrupt their native conformations, and promote the formation of protein 
aggregates (Davies, 1987; Floyd & Carney, 1992; Salvi, Carrupt, Tillement, & Testa, 2001). As 
a result, normal protein functions may be impaired, leading to amplification of proteotoxicity and 
further loss of homeostasis. In sum, restoration of redox and protein homeostasis may be 
essential for the prevention of neurodegenerative diseases. 
1.1.2 Astrocyte pathology in neurodegenerative conditions 
 Parkinson’s and Alzheimer’s pathologies are known to affect both neurons and glia, 
although the neuronal changes have been investigated more thoroughly. Specifically, the impact 
of neurodegeneration on astrocytes is less well understood. In Parkinson’s disease, astrocytes 
contain alpha-synuclein+ protein aggregations in a topographic pattern that mimics the staged 
appearance of neuronal inclusions across specific brain regions (Braak, et al., 2007; Guo, 
Wharton, Moseley, & Shi, 2007; Wakabayashi, Hayashi, Yoshimoto, Kudo, & Takahashi, 2000). 
As alpha-synuclein is a neuronal protein, these astrocytes are thought to engulf alpha-synuclein 
from the extracellular space (Miyata et al., 2012). Astrocytes have also been observed to 
accumulate beta-amyloid (1-42) in Alzheimer’s disease (Acunzo, Katsogiannou, & Rocchi, 
2012). In both diseases, there is a robust increase in glial fibrillary acidic protein (GFAP), a 
marker of astrocyte activation (Le Prince et al., 1993; Mythri, et al., 2011). Other 
neurodegenerative diseases, such as Huntington’s disease and amyotrophic lateral sclerosis may 
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also negatively impact astrocytes. Regions associated with neurodegeneration and glial 
activation in Huntington’s disease exhibit an increase in small heat shock protein defenses 
(Seidel et al., 2012). For example, astrocytes exhibit increased reactivity in the spinal cord of 
amyotrophic lateral sclerosis patients compared to control subjects(Aronica, Catania, Geurts, 
Yankaya, & Troost, 2001).  
Astrocytes are known to be less susceptible than neurons to loss of protein homeostasis 
and cell death than neurons in these conditions. For example, studies of primary neurons and 
astrocytes reveal that neurons are more susceptible to proteasome inhibitors than astrocytes 
(Dasuri et al., 2010). However, both neurons and astrocytes are known to increase heat shock 
protein expression in response to proteotoxicity (Morimoto, 2008). These observations suggest 
that both cell types can respond to and defend against proteotoxic stress. However, astrocytes 
may mount better defenses than neurons because their role is to support damaged neurons and 
build scar tissue in areas of severe injury. Alternatively, unlike most adult neurons, injured 
astrocytes may continue to proliferate in order to maintain glial population numbers.  
1.2 Ubiquitin proteasome system  
1.2.1 Ubiquitin proteasome system structure and function 
The ubiquitin proteasome system (UPS) is one of the major protein degradation systems 
in eukaryotic cells. The UPS maintains protein homeostasis by degrading damaged proteins into 
peptides that are then recycled into amino acids by peptidases. Both ubiquitin-conjugated and 
oxidized proteins are degraded by the UPS (Lecker, Goldberg, & Mitch, 2006; Shringarpure, 
Grune, Mehlhase, & Davies, 2003). Degradation of proteins through the UPS occurs within the 
catalytic 26S proteasome particle and is dependent upon adenosine triphosphate (ATP) 
(Ciechanover & Schwartz, 1994). The 26S proteasome consists of one 20S and two 19S protein 
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complexes. The 19S subunits recognize proteins tagged for degradation with ubiquitin side-
chains. The ubiquitin-conjugated proteins are then linearized to facilitate their entrance into the 
barrel-like structure of the 20S subunit. Efficient enzymatic degradation of proteins into peptides 
occurs in the 20S subunit by chymotrypsin-, trypsin-, and caspase-like enzymatic activities (D. 
H. Lee & Goldberg, 1998). 
Cytosolic proteins destined for degradation by the UPS are tagged with ubiquitin through 
three enzymatic steps (Pickart, 2001). Ubiquitin activating enzymes are designated as E1 
enzymes and hydrolyze ATP and adenylate the ubiquitin molecule. After adenylation of 
ubiquitin by E1, ubiquitin conjugating enzymes, designated as E2 enzymes, transfer ubiquitin to 
the cysteine residues of the misfolded protein. Subsequently, ubiquitin ligating enzymes 
designated as E3 enzymes catalyze the transfer of ubiquitin from E2 to the target protein. The 
target protein must be labeled with at least four ubiquitin molecules prior to its recognition by the 
proteasome (Deveraux, Ustrell, Pickart, & Rechsteiner, 1994). Finally, proteins destined for 
proteasomal degradation are tagged by ubiquitin molecules that are linked through lysine 48 of 
the adjacent ubiquitin, also known as K48-linked ubiquitin (Jacobson et al., 2009). Because of 
the essential nature of the UPS, inhibitors of this protein clearance system elicit protein 
aggregations and cell death. 
1.2.2 Impact of Parkinson’s and Alzheimer’s disease on the ubiquitin proteasome system 
Impairment of the UPS has been observed in postmortem tissue from Parkinson’s disease 
and Alzheimer’s disease patients. For example, chymotrypsin, trypsin, and caspase enzymatic 
activity are decreased in the substantia nigra of Parkinson’s disease patients relative to age 
matched controls (Cook & Petrucelli, 2009; McNaught & Jenner, 2001). Similarly, chymotrypsin 
activity of the proteasome was decreased (relative to age-matched controls) in the hippocampus 
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of brains obtained from Alzheimer’s disease patients (Keller, Hanni, et al., 2000a). Furthermore, 
the substantia nigra of Parkinson’s disease patients harbors fewer proteasomal subunits than in 
control patients (Cook & Petrucelli, 2009). Alpha-synuclein, a major component of Lewy bodies 
and Lewy neurites, is known to inhibit the activity of the UPS and to propagate proteotoxicity 
(Lindersson et al., 2004).  Under some conditions, impaired UPS activity may cause the cells to 
shift towards autophagic degradation of proteins (Cecarini et al., 2014). However, in 
neurodegenerative disorders, autophagic protein clearance is also compromised, leading to 
severe loss of protein homeostasis (Anglade et al., 1997; Cuervo, Stefanis, Fredenburg, 
Lansbury, & Sulzer, 2004; Nixon et al., 2005).  
1.2.3 Modeling impairments in the ubiquitin proteasome system 
Pharmacological inhibitors targeting the UPS elicit proteasome impairment and 
proteotoxicity and are used to model neurodegenerative diseases in vitro and in vivo (Rideout, 
Larsen, Sulzer, & Stefanis, 2001; Rideout & Stefanis, 2002; Sawada et al., 2004; F. Sun et al., 
2006). MG132 (carbobenzoxy-L-leucyl-L-leucyl-L-leucinal) is a peptide aldehyde that 
reversibly inhibits the chymotrypsin-like activity of the 26S proteasome (Alexandrova, Petrov, 
Georgieva, Kirkova, & Kukan, 2008b; Braun et al., 2005; Kisselev & Goldberg, 2001). Although 
MG132 has also been shown to inhibit proteases such as cathepsin A, cathepsin B, and calpain 
(Ostrowska, Wojcik, Omura, & Worowski, 1997; Rivett & Gardner, 2000; Shirley et al., 2005), 
all of these effects converge to elicit loss of protein homeostasis or proteotoxicity. Thus, 
experiments using MG132 are thought to model proteotoxic stress and not merely proteasome 
inhibition. Additional proteasome inhibitors with different mechanisms of action include 
lactacystin. Lactacystin is a cyclic amide that covalently binds β2 of the 20S subunit of the 
proteasome and irreversibly inhibits UPS protein clearance (D. H. Lee & Goldberg, 1998). As 
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with all inhibitors, the effects of lactacystin are not limited to the proteasome because lactacystin 
also inhibits cathepsin B (D. H. Lee & Goldberg, 1998). 
1.3 Heat shock proteins 
1.3.1 Heat shock protein biology and defense against proteotoxicity 
In response to proteotoxicity, cells are known to upregulate pro-survival molecules that 
reduce loss of protein homeostasis and combat cell death. Heat shock proteins are molecular 
chaperones that refold misfolded proteins, aid in protein degradation by the UPS and lysosome, 
and activate the unfolded protein response in the endoplasmic reticulum (Walter & Ron, 2011). 
Heat shock proteins also inhibit caspase-mediated apoptosis. Heat shock proteins can be 
constitutively expressed (e.g. heat shock cognate 70 (Hsc70)) or stress induced (e.g. heat shock 
protein 70 (Hsp70) and heat shock protein 27 (Hsp27)). These proteins are typically grouped 
into high molecular weight (e.g. Hsp70 and heat shock protein 90 (Hsp90)) and small heat 
shock proteins (e.g. Hsp27). Typically, the high molecular weight heat shock proteins are ATP-
dependent whereas the small heat shock proteins are ATP-independent (Lanneau, Wettstein, 
Bonniaud, & Garrido, 2010).  
Hsp70 is the best-studied member of the heat shock protein family and is comprised of 
three interdependent domains: N-terminal ATPase domain, peptide binding domain, and a 
helical lid domain (Lanneau, et al., 2010). The coordinated functions of these protein domains 
determine Hsp70 folding activity. A number of co-chaperones drive Hsp70-mediated protein 
degradation or protein refolding. For example, Hsp70-mediated protein degradation is 
facilitated by binding to the co-chaperones BAG1 and CHIP. BAG1 binds to the ATPase 
domain while CHIP, a ubiquitin ligase, binds to the substrate-binding domain. Alternatively, the 
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co-chaperone heat shock protein 40 (Hsp40) binds to the ATPase domain of Hsp70 to stimulate 
the refolding of proteins bound to the Hsp70-misfolded protein complex.  
In addition to refolding misfolded proteins and promoting intracellular protein 
degradation, Hsp70 attenuates oxidative stress and may be released by exosomes to work in the 
extracellular space (Taylor, Robinson, Gifondorwa, Tytell, & Milligan, 2007). For example, 
astrocytes are known to release Hsp70, which may offer protection against the proteotoxicity in 
neighboring cells (Taylor, et al., 2007). Hsp70 may also attenuate cellular damage by 
upregulating glutathione defenses. For example, Guo and colleagues have shown that over-
expression of Hsp70 increases glutathione reductase and glutathione peroxidase activity after 
oxygen glucose deprivation (Guo, et al., 2007). Hsp70, unlike Hsc70, is susceptible to oxidation 
at cysteine residues (Miyata, et al., 2012). These findings suggest that Hsp70 may be sensitive 
to oxidative stress and regulate redox cycling and glutathione defenses in additional to its 
traditional chaperone functions. Hsp70 is also known to inhibit caspase-mediated apoptosis 
(Beere et al., 2000; Ravagnan et al., 2001). Hsp27 (or the murine form Hsp25) is able to 
attenuate apoptosis in addition to its role in enhancing catalytic activity of the proteasome 
(Acunzo, et al., 2012; Lanneau, et al., 2010).  
As mentioned above, disruption of protein homeostasis usually occurs in association with 
oxidative stress. Some heat shock proteins are known to decrease oxidative stress. HO1 (also 
known as Hsp32) is involved in antioxidant defense and breaks down toxic heme into the 
reactive oxygen species scavenger biliverdin and the prosurvival molecule carbon monoxide 
(Schipper, 2011). Many studies have shown that HO1 is increased in astrocytes in 
neurodegenerative conditions, possibly as a compensatory response (Schipper, 2011; Schipper, 
Liberman, & Stopa, 1998). 
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Proteotoxicity is often measured in the cytoplasm. However, proteotoxicity is also 
observed in the endoplasmic reticulum and can be reversed through the unfolded protein 
response. Glucose-regulated protein 78 kDa (GRP78) is a member of the same chaperone 
family as Hsp70 and mediates the unfolded protein response (Walter & Ron, 2011). Heat shock 
protein 60 (Hsp60) is typically associated with mitochondrial proteotoxicity and is responsible 
for refolding misfolded proteins (Saibil, 2013), (Clare & Saibil, 2013).  
1.3.2 Inhibition of heat shock protein activity 
In order to study the role of heat shock proteins, several small molecules inhibitors have 
been developed to decrease heat shock protein activity. Inhibition of Hsp70 activity can occur 
via blockade of the ATPase and/or substrate binding domains. There are three major classes of 
Hsp70 inhibitors. VER155008, an adenosine-derived inhibitor, binds to the active site of Hsp70 
and Hsc70 to inhibit ATPase activity (Chatterjee et al., 2013; Massey et al., 2010; Schlecht et al., 
2013). MAL3-101 is an allosteric Hsp70 inhibitor and interferes with the interaction of Hsp40 
and the ATPase domain of Hsp70 (Adam et al., 2014; Fewell et al., 2004; Huryn et al., 2011). 2-
phenylethynsulfonimide (PES or pifithrin-µ) is a small molecule inhibitor and binds to the 
substrate binding domain of Hsp70 to attenuate chaperone activity (Granato et al., 2013; Kondoh 
& Osada, 2013; Leu, Pimkina, Frank, Murphy, & George, 2009; Leu, Pimkina, Pandey, Murphy, 
& George, 2011). HO1 activity can be inhibited by tin protoporphyrin IX (SnPPx), which 
competes with heme for the active site of the enzyme (Drummond & Kappas, 1981; Yoshinaga, 
Sassa, & Kappas, 1982).  
1.3.3 Heat shock protein changes in Parkinson’s disease 
As neurodegenerative diseases are characterized by the accumulation of misfolded 
proteins, heat shock proteins are often upregulated in these conditions and bound to protein 
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aggregations. For example, Hsp70 is found in Lewy bodies and Lewy neurites in Parkinson’s 
patients (McNaught, Shashidharan, Perl, Jenner, & Olanow, 2002). Increases in Hsp27 and HO1 
have been observed in astrocytes in Parkinson’s disease (Renkawek, Stege, & Bosman, 1999; 
Schipper et al., 2006). Although heat shock protein levels are increased in neurodegenerative 
conditions, their activity may not be sufficient to fully attenuate or reverse proteotoxicity. On the 
other hand, it seems likely that they are partly responsible for the slow progression of these 
disorders given their established roles in protein folding and degradation.  
1.3.4  Heat shock protein changes with aging 
Aging is thought to be the major risk factor for neurodegenerative diseases, perhaps 
because of accrual of oxidative and proteotoxic damage. Age-related increases in cellular stress 
may be attributed to a decline in proteasome and autophagic systems and an increase in 
mitochondrial dysfunction (Keller, Gee, & Ding, 2002; Keller, Huang, & Markesbery, 2000; H. 
C. Lee & Wei, 2012; Martinez-Vicente, Sovak, & Cuervo, 2005). In normal aging, protein 
aggregations often appear in the olfactory bulb (Attems, Lintner, & Jellinger, 2005). Aging has 
also been associated with degeneration of dopaminergic neurons in the substantia nigra and a 
decline in striatal dopamine levels, although other studies have failed to observe age-related 
decreases in dopamine neurons (Gibb & Lees, 1991; Kish, Shannak, Rajput, Deck, & 
Hornykiewicz, 1992; McCormack et al., 2004). Furthermore, striatal volume is known to 
decrease with age (Raz et al., 2003).  
There are conflicting reports of changes in heat shock proteins with aging. Calabrese and 
colleagues observed an age-related increase in Hsp70 in the cortex, striatum, and hippocampus, 
whereas Arumugam and colleagues observed an age-related decrease in Hsp70 in the cortex and 
striatum (Arumugam et al., 2010; V. Calabrese et al., 2004). However, many studies are in 
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agreement that Hsp25/Hsp27 expression is increased with natural aging (Dickey et al., 2009; 
Gupte et al., 2010; Schultz et al., 2001). Advancing age is associated with a decrease in GRP78 
in the cortex, striatum, and hippocampus but an increase in the substantia nigra (Alladi et al., 
2010; Arumugam, et al., 2010; Hussain & Ramaiah, 2007; Paz Gavilan et al., 2006). Hsc70 is 
reported to increase with aging in the pons, medulla, striatum, thalamus, and substantia nigra (V. 
Calabrese, et al., 2004; Unno et al., 2000). Declines in heat shock proteins may contribute to 
disruption of protein homeostasis associated with aging while increases may help mitigate age-
related proteotoxic stress.    
1.4 Astrocyte biology 
1.4.1 Neurosupportive role 
Astrocytes, once thought to be merely “brain glue,” are essential for many neuronal and 
extraneuronal functions (Allen & Barres, 2009). For example, astrocytes are the primary source 
of glutathione in the brain and can robustly upregulate heat shock protein defenses (Dringen, 
2000; Dringen, Gutterer, & Hirrlinger, 2000; Schipper, et al., 2006; Schipper, et al., 1998). As 
mentioned above, astrocytes are also known to release Hsp70 into the extracellular space via 
exosomes (Taylor, et al., 2007). Some authors have argued that astrocytes play a toxic role 
(Gouix et al., 2014; Jana & Pahan, 2010). Although this may be the case in some disease states, 
it seems likely that astrocytes are more often protective given their overwhelmingly supportive 
nature. In other words, if astrocytes were absent from the diseased brain, one would expect even 
greater neuronal injury. 
1.4.2 Primary source of brain glutathione 
Neurons and glia are both equipped to synthesize glutathione. Nevertheless, astrocytes 
are the primary source of glutathione in the central nervous system (Dringen, 2000). Astrocytes 
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can promote neuronal glutathione synthesis by releasing glutathione and glutathione precursors 
into the extracellular space. Glutathione precursors, such as glutamate and cysteine, are then 
taken up by neurons for de novo glutathione synthesis (Dringen, et al., 2000; Dringen, Pfeiffer, & 
Hamprecht, 1999).  
1.5 Glutathione  
Glutathione is the most abundant antioxidant found throughout the body and can exist in 
millimolar concentrations (Aquilano, Baldelli, & Ciriolo, 2014; Meister & Anderson, 1983). 
Glutathione plays an important role in the metabolism of xenobiotics via glutathione S-
transferase, enzymatic elimination of peroxides, and reduction of free radicals through the 
cysteine thiol. 
1.5.1 Synthesis and regulation   
Glutathione is a tripeptide molecule comprised of glutamate, cysteine, and glycine. 
Glutathione production relies on the availability of synthetic enzymes (glutamate cysteine ligase 
and glutathione synthetase) and glutathione substrates. The transcription factor nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2) regulates glutamate cysteine ligase (GCL) and glutathione 
synthetase (GS) transcription. Under basal conditions (no oxidative stress), Nrf2 is bound to 
Kelch-like ECH-associated protein (Keap1). Reactive oxygen species can react with the 
cysteines on Keap1 to elicit its dissociation from Nrf2 (Fourquet, Guerois, Biard, & Toledano, 
2010; D. D. Zhang & Hannink, 2003). Upon dissociation from Keap1, Nrf2 translocates to the 
nucleus and induces GCL and GS transcription, among other genes. If glutathione substrate and 
synthetic enzyme levels are sufficient, the first step of glutathione synthesis can proceed and 
GCL ligates glutamate and cysteine. GCL activity is regulated by modifier (GCLM) and catalytic 
(GCLC) subunits. GCLM has been shown to promote the enzymatic efficiency of GCLC (S. C. 
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Lu, 2009). In the final synthetic step, glycine is incorporated into the glutamate-cysteine 
molecule by GS (S. C. Lu, 2013).  
Cysteine availability is a rate-limiting factor in glutathione synthesis. The membrane 
transporter system xc
- is responsible for importing cystine or cysteine while exporting glutamate. 
Once imported, cystine can be converted to cysteine by cystine reductase. Astrocytes are known 
to express system xc
- and thereby obtain the cysteine necessary for glutathione synthesis. The 
prodrug N-acetyl L-cysteine (NAC) can provide the L-cysteine for the glutathione synthetic 
pathway (Zhou et al., 2015). NAC can also activate system xc
- and thereby promote glutathione 
synthesis (Baker et al., 2003). 
 The amino acid cysteine can exist in two isomeric forms: L-cysteine and D-cysteine. L-
cysteine is the highly abundant form of cysteine and can be incorporated into glutathione. D-
cysteine cannot be used in glutathione synthesis and is not readily found in cells. However, both 
L- & D-cysteine can decrease reactive oxygen species through their sulfhydryl group. The 
sulfhydryl group donates a hydrogen molecule and neutralizes free radicals. D-amino acid 
oxidase and D-aspartate oxidase interconvert L- & D-amino acids (Friedman & Levin, 2012; 
Sacchi et al., 2008). D-amino acid oxidase is thought to convert D-cysteine to L-cysteine to 
increase glutathione synthesis. Thus, D-cysteine-mediated protection in the absence of D-amino 
acid oxidase activity would be suggestive of thiol-mediated effects.      
Glutathione synthesis is a tightly regulated process. Upon exposure to oxidative stress, 
there is rapid activation of Nrf2, as outlined above, and this promotes transcription and 
translation of the enzymes that synthesize glutathione (Taguchi, Motohashi, & Yamamoto, 
2011). Conversely, cells also negatively regulate glutathione synthesis in the presence of excess 
glutathione. For example, high levels of glutathione inhibit further glutathione synthesis by 
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blocking GCL activity (Franklin et al., 2009). This process of glutathione synthesis blockade can 
be replicated with buthionine sulfoximine (BSO), a reversible, competitive inhibitor of GCL 
(Griffith, 1982; Griffith & Meister, 1979). Methionine sulfoximine and etanidazole also inhibit 
glutathione synthesis but are thought to be less specific than BSO (Griffith, 1982).  
 Aside from synthesizing glutathione, astrocytes are known to tightly regulate the oxidized 
and reduced form of glutathione. Glutathione becomes oxidized when glutathione peroxidase 
converts hydrogen peroxide into water and oxygen. This enables astrocytes to prevent oxidative 
damage from the production and accumulation of hydrogen peroxide. The oxidized form of 
glutathione is readily converted back to the reduced form by glutathione reductase. Glutathione 
is primarily found in the reduced form, permitting it to exert antioxidant effects (Owen & 
Butterfield, 2010).    
1.5.2 Changes in glutathione defenses associated with neurodegenerative diseases 
 Table 1 highlights some of the changes in glutathione and glutathione-related proteins in 
various neurodegenerative diseases (Adams, et al., 1991; Damier, et al., 1993; Maher, 2005; 
Mythri, et al., 2011; Pearce, Owen, Daniel, Jenner, & Marsden, 1997; Sian et al., 1994). A net 
decrease in glutathione relative to age-matched control patients has been observed in brain 
regions highly susceptible to Parkinson’s disease, such as the substantia nigra (Pearce, et al., 
1997; Sian, et al., 1994; Sofic, Lange, Jellinger, & Riederer, 1992). An early decrease in reduced 
glutathione in neurons of the substantia nigra may exacerbate subsequent cell death in this region 
in Parkinson’s disease. Despite the net decrease in glutathione in degenerating brain regions, a 3-
5 fold increase in total glutathione has been observed in less susceptible brain regions in 
Parkinson’s patients such as the frontal cortex, caudate nucleus, and putamen (Mythri, et al., 
2011). Furthermore, glutathione peroxidase+ astrocytes are significantly increased in the 
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substantia nigra in Parkinson’s patients relative to age-matched control subjects (Damier, et al., 
1993). Therefore, astrocytes seem to engage in some compensatory responses in 
neurodegenerative conditions. However, the compensatory increase in glutathione defenses in 
astrocytes is not sufficient to halt disease progression. Future explorations of therapies that 
enhance astrocytic glutathione defense at earlier stages of neurodegeneration or lead to even 
greater increases in glutathione defenses are highly warranted.  
The family of cytosolic glutathione S-transferase enzymes is subdivided into classes 
based upon N-terminal domain amino acid sequence (Mazzetti, Fiorile, Primavera, & Lo Bello, 
2015). Two of the cytosolic glutathione S-transferase classes are π and μ. Glutathione S-
transferase μ is primarily found in astrocytes under physiological conditions whereas glutathione 
16 
 
S-transferase π, normally found in oligodendrocytes, is found in reactive astrocytes (Arumugam, 
et al., 2010; V. Calabrese, et al., 2004; Unno, et al., 2000). Glutathione S-transferase is primarily 
recognized for its conjugation of glutathione to xenobiotics, thereby eliciting cellular protection 
(Mazzetti, et al., 2015). Glutathione S-transferase π and μ can also be protective through 
regulation of the stress kinase pathways (Adler et al., 1999; Cho et al., 2001). Both π and μ 
classes of glutathione S-transferase may be important for decreasing the oxidative stress 
associated with Parkinson’s and Alzheimer’s disease. Polymorphisms in glutathione S-
transferase π have been associated with an increased risk for developing Parkinson’s disease in 
individuals who smoke (Hussain & Ramaiah, 2007). Furthermore, loss of glutathione S-
transferase π activity is associated with increased susceptibility of dopaminergic neurons in a 
mouse model of Parkinson’s disease (Paz Gavilan, et al., 2006). Alterations in the glutathione S-
transferase π 1 gene sequence are linked to earlier cognitive decline in Alzheimer’s disease 
patients (Alladi, et al., 2010). The glutathione S-transferase μ 1 null genotype is associated with 
an earlier onset of Parkinson’s disease (V. Calabrese, et al., 2004). In addition, a significant 
association between glutathione S-transferase μ 1 null polymorphisms and Parkinson’s disease 
has been observed in Chilean populations with a strong American genetic component 
(Arumugam, et al., 2010). Consistent with these observations, a combination of the glutathione 
S-transferase μ 1 null genotype and prior exposure to pesticides is more frequently observed in 
Parkinson’s disease patients than in control subjects (McCormack, et al., 2004). Furthermore, 
Piacentini and colleagues found a positive association between glutathione S-transferase μ 1 null 
genotypes and late onset Alzheimer’s disease (Raz, et al., 2003). Thus, glutathione S-transferase 
may be a reasonable target to slow or halt neurodegenerative disease progression. 
1.5.3 Therapeutic approaches to increasing glutathione 
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 Several clinical trials have explored increasing glutathione levels as a therapeutic 
approach to blunting the progression of neurodegenerative diseases. For example, clinical trials 
have shown that NAC increases blood and brain glutathione levels in Parkinson’s patients 
(Holmay et al., 2013). Adair and colleagues showed that NAC improved some aspects of 
cognitive function in Alzheimer’s disease patients (Adair, Knoefel, & Morgan, 2001). Similarly, 
NAC dramatically improved the resolution of neurological symptoms in soldiers that 
experienced traumatic brain injury in combat settings (M. E. Hoffer, Balaban, Slade, Tsao, & 
Hoffer, 2013). NAC has also been shown to improve some of the clinical symptoms of 
schizophrenia and bipolar disorder (Attems, et al., 2005; Gibb & Lees, 1991). The beneficial 
effects of NAC in neurodegenerative and psychiatric diseases may result from enhanced 
glutathione synthesis and decreases in oxidative damage. 
1.6 N-acetyl L-cysteine  
1.6.1 Up-regulation of antioxidant response element and heat shock factor 1 
 Because NAC contains a sulfhydryl group and participates in thiol exchange reactions, it 
may interact with the cysteine residues in Keap1 and heat shock factor 1 (HSF1). HSF1 
activation results in its translocation to the nucleus and Hsp70 gene induction. This hypothesis is 
consistent with previous work showing that NAC upregulates Hsp70 in neuroblastoma cells 
under conditions of proteotoxic stress (Jiang et al., 2013). As mentioned above, Keap1 
modification via thiol exchange reactions enhances Nrf2 activity and subsequent transcription of 
genes such as those that encode for Hsp70 and those under the control of the antioxidant 
response element (Hu et al., 2006; Kwak et al., 2003). Thus, NAC may have protective effects 
through direct antioxidant activity, as a glutathione prodrug, and through thiol exchanges with 
Keap1 and HSF1 that lead to the induction of pro-survival genes. 
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1.7 Adaptations to cellular stress 
1.7.1 Preconditioning  
Cellular adaptations to stressors are often studied in the context of low level, subtoxic 
stress. Exposure to subtoxic stress often promotes endogenous defenses that improve survival 
following subsequent challenges. This phenomenon is known as preconditioning or tolerance (E. 
J. Calabrese et al., 2007). Self-protection in response to cellular stress depends both on the 
concentration and duration of the injury (Leak, 2014). Exposure to subtoxic insults may elicit the 
upregulation of endogenous defensive molecules such as Nrf2 and HO1 (Bell et al., 2011; 
Garnier et al., 2001; Xu et al., 2014).  
Many studies have established that astrocytes can be preconditioned by subtoxic stress. 
For example, hypoxic preconditioning of astrocytes enhances their neuroprotective properties 
(Sen et al., 2011). Astrocyte-mediated neuroprotection may be facilitated by an increase in 
glutamate uptake following ischemic insults. Astrocytes can then convert glutamate to glutamine 
and decrease excitotoxicity (Maragakis & Rothstein, 2006). Furthermore, transfer of astrocyte-
conditioned media from preconditioned astrocytes to neurons decreases neuron apoptosis (Saibil, 
2013). In sum, astrocytes exposed to low level cellular stressors are protected against subsequent 
insults and maintain their ability to support neuronal functions.  
Although it is well established that astrocytes and other cells can adapt to low level stress, 
it is not known if cells can adapt to severe proteotoxic stress such that they are protected against 
subsequent challenges. Instead, high levels of cellular stressors are generally thought to elicit 
additive or synergistic toxicity, as predicted by the dual hit hypothesis of neurodegeneration 
(Boger, Granholm, McGinty, & Middaugh, 2010; Sulzer, 2007; Unnithan, Choi, Titler, Posimo, 
& Leak, 2012; Zhu, Lee, Perry, & Smith, 2007). As astrocytes are known to be a highly resilient 
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cell type, they seem well suited to test the hypothesis that some cells can adapt to both subtoxic 
and toxic stress, with the latter being defined as stress that is lethal to some fraction of the 
cellular population (Walter & Ron, 2011). The slow and progressive nature of neurodegenerative 
disorders is consistent with the notion that some severely stressed cells are able to resist 
subsequent challenges better than stress-naïve cells. This process might enrich the affected brain 
region in cells that become increasingly difficult to kill, thereby delaying the progression of the 
disease, perhaps for decades. Whether severely stressed astrocytes mitigate or exacerbate 
neuronal injury is also not well understood. However, this is an important question to answer 
because if astrocytes can adapt to severe stress conditions, they might be able to support 
neighboring neurons more effectively.  
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Chapter 2 Materials and Methods 
Cortical astrocyte cultures Use of animal tissue was conducted in accordance with the NIH 
Guide for the Care and Use of Laboratory Animals following Institutional Animal Care and Use 
Committee approval. Primary cortical astrocytes were harvested as previously published (Titler, 
Posimo, & Leak, 2013). Briefly, the cerebral cortex of postnatal day 1-2 Sprague-Dawley rats 
(Charles River, Wilmington, MA) was dissected under sterile conditions and incubated in 0.25% 
Trypsin-EDTA (Cat. no. 25200, Gibco Life Technologies, Grand Island, NY) at 37 °C for 7 min 
before washes and dissociation with a 5 mL serological pipet. For dual hit studies (part I), the 
cell culture medium was comprised of Basal Medium Eagle (Cat. No. B1522, Sigma-Aldrich) 
supplemented with bovine calf serum (Cat. No. 2151, HyClone Thermo Scientific), 35 mM 
glucose (Cat. No. G8769, Sigma-Aldrich, St. Louis, MO), 1 mM L-glutamine (Cat. No. 25030-
081, Gibco, Life Technologies), 50 Units/mL penicillin, and 50 µg/mL streptomycin (Cat. No. 
15140-122, Gibco, Life Technologies). For dual hit studies (part II) and the N-acetyl cysteine 
studies, the cell culture medium was composed of Dulbecco’s modified Eagle medium (DMEM, 
Cat. no. 12100061, Gibco Life Technologies) with 10% Fetal Clone III (Cat. no. SH30109.03, 
Thermo Scientific Hyclone, Logan UT), penicillin and streptomycin (50 U/mL and 50 µg/mL, 
respectively; Cat. no. 15070, Gibco Life Technologies). Dissociated cells were counted under 
Trypan blue exclusion and 24 x 106 cells were plated on T175 flasks coated with poly-D-lysine 
(10 µg/mL; Cat. no. P0899, Sigma-Aldrich). Flasks were incubated at 37°C and 5% CO2 for 7-10 
days and non-astrocytic cells were removed by orbital shaking at 260 revolutions per minute 
overnight at 37°C. The media was removed from these flasks and replaced with fresh cell culture 
medium as described above. Astrocyte cultures were then incubated for an additional 2-3 days 
before trypsinization and plating for experimental procedures, at which point they might be 
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considered secondary astrocyte cultures. Astrocyte cultures were maintained and used for 
experiments for up to one month.  
 For Part I of the dual-hit studies, astrocytes were plated at 40,000 cells/well in 96-well 
plates for viability experiments. For Part II of the dual hit studies and the investigation of N-
acetyl cysteine (NAC), cells were plated at a density of 20,000 cells/well in 96-well plates for 
viability experiments and 6.8 × 105 cells/well in 6-well plates for Western blotting (Costar, 
Corning Incorporated, Corning, NY). Under both conditions, the astrocytes formed a confluent 
monolayer at the time of experimentation. 
Primary neuron cultures Neocortical tissue was harvested from postnatal day 1-2 Sprague 
Dawley pups as previously published (Posimo, Titler, Choi, Unnithan, & Leak, 2013). Briefly, 
primary neuronal cultures were prepared by first incubating neocortical tissue in 10 Units/mL 
papain (Cat. No. P3125, Sigma-Aldrich) for 30 min at 37 °C. The tissue was then transferred to 
10% type II-O trypsin inhibitor (Cat. No. T9253, Sigma-Aldrich) at room temperature followed 
by mechanical dissociation in Basal Medium Eagle (Cat. No. B1522, Sigma-Aldrich) 
supplemented with 10% bovine calf serum (BME/BCS, Cat. No. 2151, HyClone Thermo 
Scientific), 35 mM glucose (Cat. No. G8769, Sigma-Aldrich), 1 mM L-glutamine (Cat. No. 
25030-081, Gibco, Life Technologies), 50 Units/mL penicillin, and 50 µg/mL streptomycin (Cat. 
No. 15140-122, Gibco, Life Technologies). Cells were then plated at a density of 80,000 
cells/well in Opti-MEM (Cat. No. 51985-034, Gibco, Life Technologies) with 20 mM glucose on 
a 96 well plate coated with poly-D-lysine (1 µg/mL) and laminin (Cat. No. 354232, 1.88 µg/mL, 
Corning Incorporated). After a 2 hour incubation at 37 °C, Opti-MEM was replaced with 
Neurobasal A medium (Cat. No. 10888-022, Gibco Life Technologies) supplemented with 2% 
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v/v B27 (Cat. No. 17504-044, Invitrogen Life Technologies) and L-glutamine (1:50, Cat. No. 
25030-081, Gibco Life Technologies). Neuronal cells were treated two days after plating. 
Neuron-astrocyte co-cultures Purified cortical astrocytes (as described above) were plated and 
treated with the 1st MG132 hit or vehicle in astrocyte cell culture medium. Primary neocortical 
neurons were plated on top of cortical astrocytes in Neurobasal-A Medium. Two days after 
plating the neurons, the 2nd MG132 hit was delivered. Neuron-astrocyte co-cultures were assayed 
for viability 48 hours after the 2nd MG132 hit.  For astrocyte-conditioned media experiments, 
astrocytes were treated with 1st MG132 hit for 24 hours. Astrocyte-conditioned media from 
MG132 and vehicle-treated astrocytes were directly transferred (never frozen) to neocortical 
neurons in a 1:1 dilution in neuronal media. 
Dual-hit protocol The 1st MG132 hit or MG132 pretreatment was delivered as a 10x stock to 
astrocytes that had been plated the day before. Following a 24-hour incubation in the 1st MG132 
hit, the medium was removed and the 2nd MG132 hit or MG132 post-treatment was delivered at 
a 1x concentration in a full media exchange, which served to remove all previously applied 
MG132. After a 24-hour incubation in the 2nd MG132 hit, astrocyte viability was measured by 
blinded counts of Hoechst-stained nuclei counts or ATP levels as described in the “Cell viability 
and immunocytochemistry” and “ATP assay” sections, respectively.  All experiments involved a 
24-hour period between the 1st and 2nd MG132 hits and a 24-hour incubation between the 2nd 
MG132 hit and the assay, with the exception of data presented in Figure 9D-I and Figure 9J-L. 
MG132, N-acetyl L-cysteine, D-cysteine, and L-cysteine treatments Proteotoxic stress was 
induced 24 hours after plating with the proteasome inhibitor MG132 (Cat. No. 474790, EMD 
Millipore, Billerica, MA). MG132 was added at a final concentration of 0.1 to 0.8 µM in the 
presence or absence of 3 mM NAC (Cat. No. 160280250, Acros, Geel, Belgium). On the 
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following day, fresh NAC was added for an additional 24 h, after which cell viability was 
assessed as described below. The same procedure was followed for studies on 3 mM L-cysteine 
(Cat. No. C12, 180-0, Aldrich Chemical Company, Milwaukee, WI) and D-cysteine (Cat. No. 
C1329, Tokyo Chemical Industry, Tokyo, Japan).  
Pharmacological inhibitors Buthionine sulfoximine was used as a competitive inhibitor of the 
rate limiting enzyme glutamate-cysteine ligase (Cat. No. 309475000, Acros) (Griffith & Meister, 
1979). Ammonium chloride was used to inhibit all types of autophagy by increasing the 
lysosomal pH (NH4Cl, 20 mM; Acros Organics, Somerset NJ). VER155008 (Cat. No. 3803, 
Tocris Bioscience, Minneapolis, MN) was used as an ATPase activity inhibitor of Hsp70/Hsc70 
(Chatterjee, et al., 2013; Massey, et al., 2010; Saykally et al., 2012). Pifithrin-µ (2-
phenylethynesulfonamide, Cat. No. 506155, EMD Millipore) was used to bind and inhibit the 
substrate-binding domain of Hsp70/Hsc70 (Balaburski et al., 2013; Granato, et al., 2013; 
Kondoh & Osada, 2013; Leu, et al., 2009; Leu, et al., 2011; Schlecht, et al., 2013). The third 
Hsp70/Hsc70 inhibitor, MAL3-101 (provided by Drs. Peter Wipf and Jeffrey Brodsky), 
interferes with Hsp40-mediated ATP hydrolysis by Hsp70/Hsc70 (Adam, et al., 2014; Braunstein 
et al., 2011; Hatic, Kane, Saykally, & Citron, 2012; Huryn, et al., 2011; Kilpatrick et al., 2013). 
Sodium benzoate (Cat. No. AC447802500, Acros) and used to inhibit the conversion between D- 
and L-cysteine by D-amino acid oxidase (Katane et al., 2013). Tin (IV) protoporphyrin IX 
dichloride (SnPPx, Cat. no. Sn749-9, Frontier Scientific, Logan, Utah), competes for heme at the 
heme oxygenase 1 active site and therefore inhibits the conversion of heme into bilirubin and 
carbon monoxide (Drummond & Kappas, 1981; Yoshinaga, et al., 1982). Pharmacological 
inhibitors were added at the same time as MG132 and NAC.  
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Cell viability and immunocytochemistry Cell viability was measured following nuclear 
staining with the Hoechst reagent. Upon the completion of the experiment, astrocytes were fixed 
in 3% paraformaldehyde (Cat. No. 9990244, Thermo Scientific, Pittsburgh, PA) and 3% sucrose 
(Cat. No. 0389, Sigma-Aldrich, St. Louis, MO) in phosphate buffer for 20 min at room 
temperature and washed three times with 10 mM PBS. Cells were then stained with Hoechst 
33258 (5 µg/mL, bisBenzimide, Sigma-Aldrich) diluted in PBS for 20 min. Images of Hoechst-
stained nuclei were captured on an EVOS microscope (Model #AMF 4301 US, Advanced 
Microscopy Group, Bothell WA) in the 3 o’clock and 9 o’clock position in each well. ImageJ 
software (NIH Image, Bethesda, MD) was then used for blinded cell counts of the number of 
Hoechst-stained nuclei at 200x magnification. 
For immunocytochemistry, astrocyte cultures and neuron-astrocyte co-cultures were 
washed in PBS, and blocked for 30 min in Odyssey Block (LI-COR Bioscience, Lincoln, NE) 
diluted 1:1 in PBS. Primary antibodies were prepared in Odyssey Block/PBS (1:1) with 0.3% 
Triton X-100 as indicated in Table 2. Cells were incubated in primary antibody solutions 
overnight at 4 oC. On the following day, cells were washed three times with PBS. Secondary 
antibodies (see Table 3) were diluted in 1:1 Odyssey Block/PBS and 0.3% Triton X-100 and 
applied to cells for 1 hour at room temperature. Finally, the secondary antibody was removed by 
three washes before microscopy on the EVOS microscope or LI-COR Odyssey Imager.   
ATP assay ATP levels were measured by the luminescent CellTiter-Glo Assay with minor 
modifications (Cat. no. G7572, Promega, Madison, WI), as previously published (Posimo et al., 
2014; Titler, et al., 2013). Astrocytes were lysed and incubated in CellTiter-Glo reagent at a 1:2 
ratio in astrocyte cell culture medium (25 μL CellTiter-Glo: 50 μL media). Luminescence was 
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measured on a luminometer (VICTOR3 1420 multilabel counter; PerkinElmer, Waltham, MA) 
after a 15 min incubation period.  
Total and reduced glutathione measures. The In-Cell Western technique was used to assess 
total glutathione levels. Glutathione measures were expressed as a fraction of α-tubulin signal 
and Hoechst- or DRAQ5-stained nuclei in the same well to account for differences in cell 
density. Reduced glutathione levels were measured by the luminescent GSH-Glo assay according 
to the manufacturer’s instructions (Cat. no. V6911, Promega, Madison, WI). Reduced 
glutathione levels were expressed as a function of Hoechst-stained nuclei on parallel plates to 
account for differences in cell density. 
Immunoblotting. Whole cell lysates were collected in cell lysis buffer (recipe from Cell 
Signaling Technologies, Danvers, MA, Cat. no. 9803) supplemented with protease inhibitor 
cocktail (1:50; Cat. no. P8340, Sigma-Aldrich) and 10 mM sodium fluoride (Leak, Castro, 
Jaumotte, Smith, & Zigmond, 2010), 24 h or 48 h following treatments. The samples were then 
sonicated with a probe and protein concentrations were measured by the bichinchoninic assay.  
Ten micrograms of each sample were loaded on a 10% polyacrylamide gels and subjected to 
electrophoresis. Separated proteins were then transferred to Immobilon-FL polyvinylidene 
fluoride or nitrocellulose membranes (EMD Millipore). Following the transfer, membranes were 
subjected to three Tris-buffered saline (TBS) washes before the blocking step in 5% nonfat dry 
milk in TBS or Odyssey block diluted 1:1 in TBS (Cat. no. 927-40000, LI-COR). Primary 
antibodies (Table 2) were prepared in TBS with 0.1% Tween and 5% bovine serum albumin 
fraction V (Research Products International, Mount Prospect, IL) or Odyssey block diluted 1:1 in 
TBS with 0.1% Tween. Secondary antibodies (Table 3) were diluted in TBS with 5% nonfat dry 
milk and 0.1% Tween or in Odyssey block diluted 1:1 in TBS with 0.1% Tween. Immunolabeled 
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blots were then washed in TBS with 0.1% Tween and fluorescent signal was assessed on a LI-
COR Odyssey Imager. The data was quantified by Odyssey software (Ver 3.0; LI-COR) or 
Image Studio Lite software (LI-COR).  
Tissue collection for in vivo aging study Protocols for obtaining tissue in this study were 
approved by the Duquesne University Institutional Animal Care and Use Committee and 
conducted in compliance with the NIH Guide for the Care and Use of Laboratory Animals. 
Female Sprague Dawley rats (Charles River, Wilmington, MA) were generated in an in-house 
breeding colony and aged to 22 months. Animals were sacrificed by 22 months of age due to 
poor health at older ages. Animals were anesthetized with 5% isoflurane immediately prior to 
decapitation and tissue microdissection. The boundaries of the olfactory bulb, substantia nigra, 
and striatum were defined according to the Paxinos rat atlas (George Paxinos, 1998). All animals 
were sacrificed within 48 h of each other and processed together. In addition, three young female 
rats (2-4 months old) were perfused with 4% paraformaldehyde for immunofluorescent staining 
of heat shock proteins. Fixed brains were cryoprotected in 30% sucrose in phosphate-buffered 
saline and cut at 40 microns on a freezing microtome (Microm HM450, Thermo Scientific, 
Pittsburgh, PA) (Crum et al., 2015b; Gleixner et al., 2014). 
Immunohistochemistry Coronal sections through the substantia nigra were immunolabeled with 
Hsp25, Hsp60, and HO1 antibodies in conjunction with antibodies raised against the 
dopaminergic phenotype marker tyrosine hydroxylase. All sections were blocked with Odyssey 
Block diluted in 1:1 in PBS for 1h at room temperature. Sections were then incubated overnight 
at 4oC in primary antibodies diluted in PBS with 0.3% Triton X-100. Unbound primary 
antibodies were washed off with three exchanges of PBS before incubation in secondary 
antibodies for 1hr at room temperature. After the secondary antibody incubations, tissue sections 
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were washed, mounted onto glass slides, and coverslipped with Fluoromount-G (Cat. no. 0100-
01, Southern Biotech, Birmingham, AL). A confocal microscope was used to examine protein 
expression patterns (Leica TCS SP2, Wetzlar, Germany). For the primary and secondary 
antibody dilutions and sources, please see Tables 2 and 3. The following controls were used for 
each antibody examined by immunohistochemistry: 1) exposure to all solutions except both 
primary antibodies and 2) exposure to one primary antibody only, followed by exposure to both 
secondary antibodies (Crum, et al., 2015b). 
Statistical analyses Statistical significance was determined with SPSS Statistics (IBM, Version 
10.0, Armonk, NY) or GraphPad Prism (Version 6, La Jolla, CA) software. Data were subjected 
once to the Grubb’s outlier test. For experiments with two groups, the Student’s t test was used 
and for experiments with more than two groups a two- or three-way ANOVA with the 
Bonferroni post hoc correction was employed. Each experiment was conducted on at least three 
separate occasions. Furthermore, each experiment was conducted in triplicate or quadruplicate 
wells. Triplicate or quadruplicate data were averaged for an n=1 only. For Western blotting 
experiments, samples were collected on a minimum of three separate occasions. Changes were 
only deemed significant when p 0.05.  All data are presented as the mean  standard error of 
the mean. 
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Chapter 3 Results 
3.1 Exposure to severe proteotoxic stress elicits tolerance in surviving astrocytes and 
does not abolish their neuroprotective role 
Part I. 
Characterization of cortical astrocyte cultures 
 We began these studies by developing a model of proteotoxic stress in cortical 
astrocyte cultures harvested from postnatal rat pup brains. In order to characterize the 
purity of the cortical astrocyte cultures, cells were immunolabeled for glial markers glial 
fibrillary acidic protein (GFAP) and S100β and stained with the nuclear marker Hoechst 
(Fig 1a-d lower magnification, Fig 1e-h higher magnification). Large, Hoechst+ nuclei 
stained positive for GFAP and S100β or for S100β alone (long-stemmed arrows), 
whereas smaller nuclei were only GFAP+ (short-stemmed arrows). Shrunken, condensed 
nuclei did not stain for either glial marker, perhaps because they were undergoing 
apoptosis and lost the glial phenotype (Fig. 1g). The purity of the astrocyte cultures was 
then determined by counting the number of GFAP+ cells, S100β+ cells, and cells that did 
not stain for either glial cell marker, all expressed as a percentage of total Hoechst+ cell 
numbers. Primary cultures derived by the abovementioned protocol contained 83% 
GFAP+ cells and 87% S100β+ cells, whereas 8% of the cells did not stain positive for 
either astrocyte marker (Fig 1i).  
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Figure 1. Cortical astrocyte culture 
purity in Basal Medium Eagle. a-h 
Astrocytes were 
immunocytochemically labeled for 
S100β (a and e; green) and GFAP (b 
and f; red) as well as stained for 
nuclear marker Hoechst (c and g; 
blue). The center of the image in a-d 
was photographed at a higher 
magnification in e-h. Cellular 
morphologies fell into three anatomical 
categories. Cells with large, flat nuclei 
were labeled with both S100β and 
GFAP or only with S100β (long-
stemmed arrows, g). Cells with smaller 
and brighter nuclei were positive for 
GFAP only (short-stemmed arrow). 
Condensed, fragmented nuclei lacked 
both markers, perhaps because they 
were apoptotic cells that lost their 
normally glial phenotype (arrowhead). 
i: Quantification of Hoechst-labeled 
nuclei that were positive for either 
GFAP (light gray bar) or S100β (dark 
gray bar), or negative for either marker 
(black bar). n=3 independent 
experiments. Reprinted from 
“Astrocyte plasticity revealed by 
adaptations to severe proteotoxic 
stress,” by A. M. Titler, 2013, Cell 
Tissue Research, 352, 427-443. 
Copyright [2013] by A.M Titler. 
Reprinted with permission. 
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Proteotoxic stress elicits stress tolerance in astrocytes 
Stress adaptations are often studied in the context of low-level or subtoxic 
stressors. For example, exposure to subtoxic ischemic insults decreases astrocyte 
susceptibility to subsequent ischemic insults, a phenomenon known as preconditioning or 
stress tolerance (Pang et al., 2015). In contrast, severe stress is generally thought to 
weaken cells and to exacerbate the toxic response to subsequent insults. We define severe 
stress as stress that kills some fraction of the cellular population under study. Because 
astrocytes are more resistant than many other types of brain cells, we hypothesized that 
astrocytes surviving severe stress may mount adaptive defenses and tolerate subsequent 
insults better than naïve astrocytes. If this hypothesis were supported, it would suggest 
that stress can elicit protective and not always toxic stress responses even when the stress 
is high in concentration. This hypothesis lies in contrast with traditional views of the 
stress response, which hold that cells can only mount adaptive defenses against mild 
stress (E. J. Calabrese, 2008). 
In order to test whether astrocytes that survive high levels of proteotoxic stress 
would be more or less susceptible to subsequent insults, we developed a dual hit model. 
Proteotoxic stress, or stress associated with loss of protein homeostasis, was induced with 
the proteasome inhibitor MG132. MG132 was chosen because proteotoxicity is a major 
hallmark of all neurodegenerative disorders (Gundersen, 2010; Keller, Hanni, et al., 
2000a; Morimoto, 2008) and it is a well characterized and commonly used toxin (D. H. 
Lee & Goldberg, 1998). Cortical astrocytes were first exposed to toxic concentrations of 
MG132; this is referred to as the MG132 pretreatment. In order to assess the effect of the 
initial MG132 insult, the surviving glial population was challenged a second time with 
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toxic concentrations of MG132 to see if the astrocytes were resistant to subsequent 
insults. The second exposure to MG132 is referred to as the MG132 post-treatment.  
Increasing concentrations of MG132 pretreatment elicited morphological changes 
consistent with astrocyte stress reactivity, as visualized by increases in GFAP and S100β 
immunostaining (Fig 2a). Similarly, increasing concentrations of MG132 post-treatment 
led to cytoskeletal condensation and retraction of astrocytic processes (Fig 2b), 
suggestive of cellular stress (Sofroniew & Vinters, 2010; Tynan et al., 2013). 
Quantification of the number of Hoechst+ cells revealed that MG132 pre- and post-
treatment alone led to a significant decrease in astrocyte viability (48h or 24h after 
treatment, respectively) (Fig 2c & d). As expected, astrocytes that survived MG132 
pretreatment were resistant to 60 and 80 µM MG132 post-treatment. In other words, there 
was no additional decrease in viability in response to MG132 post-treatment when 
astrocytes had been pretreated with MG132. However, previously stressed astrocytes 
were unable to tolerate the toxicity associated with 160 µM MG132 post-treatment. 
These data suggest that stressed astrocytes are resistant to subsequent insults but that 
there is a threshold beyond which they no longer maintain tolerance. In order to 
determine whether severe proteotoxic stress was eliciting significant loss in cell numbers 
at the time of post-treatment, astrocyte viability was assessed 24h after MG132 
pretreatment (Fig 2e). As expected, MG132 pretreatment (0.20-0.80 µM) significantly 
decreased astrocyte viability at the time of MG132 post-treatment. Furthermore, there 
was no significant difference in viability between 24 and 48h after MG132 pretreatment. 
These findings suggest that the weaker astrocytes have already died at the time of 
delivery of post-treatment and that there is no additional cell loss in the next 24h interval. 
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Figure 2. Severe proteotoxic stress renders astrocytes protected against subsequent insults 
a: Photomontage of GFAP, S100β and Hoechst labeled astrocytes following treatment with 
indicated concentrations of MG132. MG132 was applied the day after plating (pretreatment or 
1st hit paradigm). Two days later, cells were fixed, immunostained, and photographed. Cell loss 
was apparent at concentrations of 0.2 µM and beyond. b: Photomontage of GFAP, S100β and 
Hoechst labeled astrocytes following treatment with indicated concentrations of MG132. Cells 
were treated with MG132 two days after plating (post-treatment or 2nd hit paradigm). Much 
higher concentrations of MG132 (60 µM and beyond) were needed to elicit cell loss in the post-
treatment paradigm, perhaps because cells had been plated 2 days before and were much better 
attached. c: MG132 pretreatments and post-treatments were combined and viability assessed 
with counts of Hoechst-positive nuclei. Increasing shades of gray indicate higher concentrations 
of MG132 post-treatment. The lightest gray bars indicate pretreatment alone (0 µM MG132 
post-treatment). d: A representative photomontage of cells treated with 0.4 µM pretreatment, 80 
µM post-treatment, and the combination of both is shown on the right of the quantification. Cells 
pretreated with an LC50 concentration of 0.4 µM MG132 were protected against additional loss 
of nuclei when post-treated with a normally LC50 concentration of 80 µM MG132. e: Cells were 
pretreated with indicated concentrations of MG132 and assayed either 24 h later or 48 h later for 
viable nuclei. There was no difference in viability between cells collected at the two timepoints. 
n=3 independent experiments. * p ≤ 0.05 versus MG132 pretreatment alone (0 µM post-
treatment), + p ≤ 0.05 versus MG132 post-treatment alone (0 µM MG132 pretreatment), two-
way ANOVA followed by Bonferroni post hoc test. Reprinted from “Astrocyte plasticity 
revealed by adaptations to severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue 
Research, 352, 427-443. Copyright [2013] by A.M Titler. Reprinted with permission. 
35 
 
Stress tolerance is associated with preservation of metabolic function 
 ATP levels reflect metabolic health and are often used as an indicator of cell 
viability (Crouch, Kozlowski, Slater, & Fletcher, 1993; Petty, Sutherland, Hunter, & 
Cree, 1995; Unnithan, et al., 2012). Therefore, we used a luminescent assay for ATP 
levels, CellTiter Glo, to complement the Hoechst cell count data. However, changes in 
ATP did not precisely coincide with changes in the number of Hoechst+ nuclei in this 
model, consistent with other reports from our group (Posimo, et al., 2014).  For example, 
ATP levels were not decreased by MG132 pretreatment alone as had been shown for 
Hoechst+ cell numbers (Fig 3a). However, a concentration-dependent decrease in ATP 
was observed in response to MG132 post-treatment in cells that had not been previously 
stressed. In contrast, MG132-pretreated astrocytes showed no significant decrease in ATP 
levels in response to MG132 post-treatment, except in the 0.10 µM pretreatment and 80 
µM post-treatment groups.  These data suggest that severe proteotoxic stress prevents the 
loss of ATP in response to MG132 post-treatment, consistent with stress-induced 
protection of metabolic function. In order to force ATP loss, we also applied 100-fold 
higher MG132 pretreatment concentrations (Fig 3b). Even at these extremely high 
concentrations of MG132 pretreatment (10 to 80 µM MG132; sufficient to yield ATP 
loss), previously stressed astrocytes were able to maintain ATP levels in response to post-
treatment (80 µM MG132).  
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Figure 3. Impact of severe proteotoxic stress on ATP a: Viability following pretreatment and 
post-treatment was assessed with the Cell Titer Glo assay for ATP. ATP levels did not fall with 
pretreatment even though cell number was lower by parallel counts of Hoechst stained nuclei in 
Figure 2. However, ATP levels did fall with post-treatment under control conditions (no 
pretreatment). In contrast, cells that were pre-stressed with MG132 were protected against the 
ATP loss caused by post-treatment. n=3 independent experiments. b: ATP assay following 10-fold 
higher pretreatment concentrations of MG132 that did elicit ATP loss. Pretreated cells were 
completely protected against the usual loss of ATP in response to 80 µM MG132. n=3 
independent experiments. * p ≤ 0.05 versus MG132 pretreatment alone (0 µM post-treatment), + p 
≤ 0.05 versus MG132 post-treatment alone (0 µM MG132 pretreatment), two-way ANOVA 
followed by Bonferroni post hoc test. Reprinted from “Astrocyte plasticity revealed by adaptations 
to severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue Research, 352, 427-443. 
Copyright [2013] by A.M Titler. Reprinted with permission. 
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Severe proteotoxic stress leads to upregulation of cellular defenses   
 We hypothesized that high concentrations of MG132 would elicit proteotoxic 
stress and the upregulation of cellular defenses. As an indicator of proteotoxicity, we 
measured ubiquitin-conjugated proteins by Western blot analysis. Ubiquitin is attached to 
misfolded proteins in order to tag them for proteasomal degradation (Lecker, et al., 
2006). Application of proteasomal inhibitors, such as MG132, is expected to elicit an 
increase in ubiquitinated proteins because the tagged proteins can no longer be degraded. 
In cells not exposed to MG132 pretreatment, MG132 post-treatment elicited a dramatic 
increase in ubiquitin-conjugated proteins, demonstrating proteotoxic stress (Fig 4a). 
Furthermore, there was an even greater increase in ubiquitin-conjugated proteins in 
response to the dual hits. These findings suggest that astrocytes respond to MG132 post-
treatment with a sharp increase in protein misfolding, and that this response is still 
evident and even greater when cells have been previously exposed to MG132 
pretreatment. Thus, previously stressed astrocytes are resistant to subsequent proteotoxic 
insults despite evidence of severe proteotoxic stress. Importantly, the results also show 
that previously stressed astrocytes are not simply refractory to the MG132 toxin and can 
still respond to continued proteotoxic stress. For example, we have not simply enriched 
our cultures in cells that fail to take up the MG132 toxin and so do not respond to the 
post-treatment either. Further evidence that severely stressed astrocytes still respond to 
post-treatment was gathered by measurements of HO1, which is known to be induced by 
cellular stress and to engage in antioxidant defense (Fig 4b) (Schipper, et al., 2006; 
Schipper, et al., 1998; Schipper, Song, Zukor, Hascalovici, & Zeligman, 2009). MG132 
post-treatment elicited a dramatic increase in HO1 in MG132-pretreated astrocytes 
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whether or not they had been exposed to MG132 pretreatment. Again, these results are 
inconsistent with the notion that stressed astrocytes are refractory to further MG132 
toxicity. These data also demonstrate that the stressed astrocytes mount active defenses 
against protein misfolding stress. In sum, the HO1 and ubiquitin-conjugated proteins data 
confirm that previously stressed astrocytes still take up MG132 and respond to post-
treatment, but nevertheless resist additional cell death. 
 It has been known for many decades that the folding chaperone Hsp70 is 
upregulated in response to protein misfolding stress (Mayer & Bukau, 2005). This was 
also observed in our studies as MG132 post-treatment significantly increased Hsp70 
levels (Fig 4c). However, MG132 pretreatment blunted the effect of MG132 post-
treatment on Hsp70 levels. Similar to HO1 and Hsp70, GFAP is a highly stress-
responsive protein (Middeldorp & Hol, 2011). As an additional measure of cellular stress 
in our model, we investigated the effect of MG132 pre- and post-treatment on GFAP 
levels. MG132 pretreatment significantly increased GFAP as expected (Fig 4d). No 
additional effect of post-treatment on GFAP was observed in pretreated cells. These 
results show that the impact of post-treatment on two stress-responsive proteins, Hsp70 
and GFAP, is blunted by pretreatment.  
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Figure 4. Severe proteotoxic stress elicits the upregulation of protein defenses. Western 
immunoblotting on astrocytes treated with 0.4 µM MG132 pretreatment, 80 µM MG132 post-
treatment, and the combination of two hits. Representative infrared images of protein bands 
were pseudocolored red or green and are shown adjacent to the quantification (see arrows) for 
ubiquitin-conjugated proteins (a, n=6 independent experiments), heme oxygenase 1 (b, HO-1; 
n=6 independent experiments), heat shock protein 70 (c, Hsp70, n=6 experiments), and GFAP 
(d, n=3 independent experiments). Gray bars indicate 0 µM MG132 post-treatment. Black bars 
indicate 80 µM MG132 post-treatment. All proteins are expressed as a fraction of cytoskeletal 
β-actin levels. * p ≤ 0.05 for 0 µM versus 80 µM MG132 post-treatment, + p ≤ 0.05 versus 
MG132 post-treatment alone (0 µM MG132 pretreatment), two-way ANOVA followed by 
Bonferroni post hoc test. Reprinted from “Astrocyte plasticity revealed by adaptations to 
severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue Research, 352, 427-443. 
Copyright [2013] by A.M Titler. Reprinted with permission. 
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Autophagy inhibition does not reduce stress tolerance in astrocytes  
 Autophagy is an alternative clearance system that removes misfolded proteins and 
damaged organelles (Arias & Cuervo, 2011). Proteasome inhibition is known to 
upregulate autophagy as a compensatory response (Ding et al., 2007; Korolchuk, 
Menzies, & Rubinsztein, 2010). This raises the possibility that stressed astrocytes can 
tolerate subsequent MG132 post-treatment because they transition from protein 
degradation by the UPS to autophagy at times of UPS inhibition. Thus, astrocytes were 
stained for a marker of chaperone-mediated autophagy, LAMP2a (Fig 5a-d) (Kaushik & 
Cuervo, 2012). Qualitative assessments of LAMP2a levels reveal that this protein was 
increased in the dual hit group. This suggests that stressed astrocytes may upregulate 
autophagic systems to defend against subsequent proteotoxic stress. Therefore, we 
inhibited all forms of autophagy with ammonium chloride and assessed astrocyte 
viability (R. Sun et al., 2015). However, inhibition of autophagy did not decrease the 
stress-induced resilience in our model (Fig 5e). These findings suggest that stressed 
astrocytes do not rely on autophagy for stress tolerance.  
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Figure 5. Astrocytes do not rely on 
autophagy for resilience. a-d 
Immunocytochemistry for lysosome-
associated membrane protein type-2a 
(LAMP2a, red) in astrocytes treated with 80 
µM MG132 post-treatment (b), 0.4 µM 
MG132 pretreatment (c), and the 
combination of two hits (d). Nuclei were 
stained with Hoechst (blue). LAMP2a was 
found in a perinuclear anatomical location, 
as expected from a lysosomal marker, and 
was highest in the astrocytes treated with 
two hits (0.4 µM pretreatment + 80 µM 
post-treatment). e: Nuclear viability of 
astrocytes treated with 0.4 µM MG132 
pretreatment, 80 µM MG132 post-treatment, 
and the combination of two hits, in the 
presence or absence of autophagy inhibitor 
ammonium chloride (20 mM NH4Cl). Gray 
bars indicate 0 µM MG132 post-treatment. 
Black bars indicate 80 µM MG132 post-
treatment. Pretreated astrocytes did not 
respond to post-treatment with additional 
cell loss and NH4Cl had no effect on this 
pattern. n=3 independent experiments. * p ≤ 
0.05 for 0 µM versus 80 µM MG132 post-
treatment, + p ≤ 0.05 versus MG132 post-
treatment alone (0 µM MG132 
pretreatment), two-way ANOVA followed 
by Bonferroni post hoc test. Reprinted from 
“Astrocyte plasticity revealed by adaptations 
to severe proteotoxic stress,” by A. M. 
Titler, 2013, Cell Tissue Research, 352, 427-
443. Copyright [2013] by A.M Titler. 
Reprinted with permission. 
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Inhibition of glutathione synthesis attenuates stress tolerance in astrocytes 
 Glutathione is one of the most abundant cellular antioxidants and astrocytes are 
the primary source of glutathione in the brain (Dringen, 2000; Makar et al., 1994; Slivka, 
Mytilineou, & Cohen, 1987). In Parkinson’s disease, astrocytes retain and/or upregulate 
glutathione levels despite loss of glutathione in neighboring neurons (Damier, et al., 
1993; Mythri, et al., 2011). Therefore, we hypothesized that astrocytes rely on 
glutathione to defend against severe proteotoxic stress. In order to test the importance of 
glutathione in the dual hit model, glutathione synthesis was inhibited with buthionine 
sulfoximine (BSO) (Griffith, 1982; Griffith & Meister, 1979). BSO successfully 
decreased total glutathione levels at subtoxic concentrations (Fig 6a-c). MG132 
pretreatment completely prevented the loss of total glutathione in response to MG132 
post-treatment, suggesting that stressed astrocytes may rely on glutathione to survive a 
second challenge and BSO abolished this effect (Fig 6d-f). As expected, loss of 
glutathione sensitized MG132-pretreated astrocytes to MG132 post-treatment. In other 
words, previously stressed astrocytes showed a 42% decrease in viability in response to 
MG132 post-treatment under conditions of glutathione loss (Fig 7a-i). This suggests that 
stressed astrocytes rely on glutathione synthesis to tolerate subsequent MG132 insults. 
BSO did not alter ATP levels in stressed astrocytes (Fig 7j). Thus, ATP levels again 
failed to coincide with the number of Hoechst+ nuclei.  
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Figure 6. Buthionine sulfoximine attenuates the rise in glutathione with proteotoxic stress. a 
Impact of buthionine sulfoximine (BSO), an inhibitor of glutathione (GSH) synthesis, on glutathione 
levels (expressed as a fraction of cytoskeletal α-tubulin levels; gray bars) and on nuclear viability 
(black bars). n=3 independent experiments. Representative images of Hoechst-stained nuclei treated 
with indicated concentrations of buthionine sulfoximine are illustrated in b. Representative infrared 
images of the glutathione assay (pseudocolored green) and α-tubulin levels (pseudocolored red) are 
shown in c. From these data, the 12.5 µM buthionine sulfoximine concentration was chosen for 
subsequent experiments because it reduced glutathione levels without causing any cell death. d: 
Glutathione levels (expressed as a fraction of α-tubulin) in astrocytes treated with 0.4 µM MG132 
pretreatment, 80 µM MG132 post-treatment, and the combination of two hits, in the absence or 
presence of 12.5 µM buthionine sulfoximine. Gray bars indicate 0 µM MG132 post-treatment. Black 
bars indicate 80 µM MG132 post-treatment. Glutathione levels fell with 80 µM MG132 post-
treatment, but were completely rescued by pretreatment with 0.4 µM MG132 in the absence of 
buthionine sulfoximine. In the presence of buthionine sulfoximine, glutathione levels were depressed 
in all groups except the 80 µM post-treatment alone group. n=3 independent experiments. 
Representative infrared images of glutathione (green) and α-tubulin levels (red) are shown in e and f, 
respectively. * p ≤ 0.05 0 µM versus 80 µM MG132 post-treatment, + p ≤ 0.05 versus MG132 post-
treatment alone (0 µM MG132 pretreatment), and ^ p ≤ 0.05 versus 0 µM buthionine sulfoximine 
(H2O vehicle), two-way ANOVA followed by Bonferroni post hoc test. Reprinted from “Astrocyte 
plasticity revealed by adaptations to severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue 
Research, 352, 427-443. Copyright [2013] by A.M Titler. Reprinted with permission. 
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Figure 7. Stressed astrocytes rely on glutathione in order to remain resilience. a 
Nuclear viability in astrocytes treated with 0.4 µM MG132 pretreatment, 80 µM 
MG132 post-treatment, and the combination of two hits, in the absence or presence of 
12.5 µM buthionine sulfoximine. Gray bars indicate 0 µM MG132 post-treatment. 
Black bars indicate 80 µM MG132 post-treatment. Buthionine sulfoximine rendered 
pretreated cells sensitive to 80 µM MG132 post-treatment, as they were no longer 
protected against additional cell loss. n=4 independent experiments. b-i: 
Representative images of Hoechst-stained nuclei in astrocytes treated with 0.4 µM 
MG132 pretreatment, 80 µM MG132 post-treatment, and the combination of two hits, 
in the absence or presence of 12.5 µM buthionine sulfoximine. Note the enhancement 
of the toxicity of two hits in the presence of buthionine sulfoximine. j: ATP levels of 
astrocytes treated in the same format as in a. Astrocytes were still protected against 
additional ATP loss even in the presence of buthionine sulfoximine. n=3 independent 
experiments. * p ≤ 0.05 0 µM versus 80 µM MG132 post-treatment, and + p ≤ 0.05 
versus MG132 post-treatment alone (0 µM MG132 pretreatment),  two-way ANOVA 
followed by Bonferroni post hoc test. Reprinted from “Astrocyte plasticity revealed 
by adaptations to severe proteotoxic stress,” by A. M. Titler, 2013, Cell Tissue 
Research, 352, 427-443. Copyright [2013] by A.M Titler. Reprinted with permission. 
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Part II.  
 Our next set of dual hit studies was conducted at a lower plating density due to 
rapid cell growth and in a less expensive cell culture medium. Therefore, astrocyte 
cultures were reevaluated in this new model, in collaboration with an undergraduate 
student, Deepti Pant. Astrocyte culture purity was slightly higher with the new protocol: 
89.6% of the cells were GFAP+, 91.8% were S100β+, and 6.1% of the cells did not stain 
positive for either marker (Fig 8). As described in Part I, viable astrocytes were 
quantified by measuring the number of Hoechst+ cells. In the dual hit studies of Part II we 
used the automated cell counting function in ImageJ software (NIH Image). Hoechst+ 
cells undergoing cell death typically display shrunken, condensed nuclei. Therefore, 
Hoechst+ nuclei with areas less than 350 pixels (53 µm2) were excluded in the viability 
measurements. Representative images of such cells are illustrated in Figure 8C &D.  
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Figure 8. Cortical astrocyte culture 
purity in Dulbecco’s Modified Eagle 
Medium. A) Cortical astrocytes were 
stained with the nuclear marker 
Hoechst and immunolabeled for the 
glial markers glial fibrillary acid 
protein (GFAP) and S100β. B) The 
percentage of Hoechst+ cells that were 
immunolabeled for GFAP or S100β 
proteins or were immunonegative were 
quantified. C) Representative image of 
Hoechst-stained nuclei in untreated 
astrocytes. White arrow points to one 
cell with a condensed nucleus.  D) The 
image in C was converted to a binary 
image using the threshold function in 
Image J. Nuclear cross-sectional areas 
appear next to each cell in square 
microns. Cells with nuclear areas 
under 350 pixels (53 µm2, see black 
arrow) were excluded from the counts 
of viable cells in subsequent figures. 
Reprinted from “Astrocytes surviving 
severe stress can still protect 
neighboring neurons from proteotoxic 
stress,” by A. M. Gleixner, 
2015, Molecular Neurobiology, Epub 
ahead of print. Copyright [2015] by 
A.M Gleixner. Reprinted with 
permission. 
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Long-lasting stress tolerance in astrocytes 
 In addition to reevaluating astrocyte cultures with the new protocol, the LC50 
concentrations of MG132 also had to be reevaluated. For the sake of simplicity, we 
changed the name of the pretreatment to the 1st MG132 hit and the post-treatment to the 
2nd MG132 hit. Toxic 1st and 2nd MG132 hit concentrations first had to be identified in 
the new dual hit protocol. Despite several protocol modifications, toxic concentrations of 
the 1st hit (0.16-0.64 µM) still elicited tolerance against a toxic 2nd hit (3.125 µM) (Fig 
9A-C). The 2nd hit concentration in these studies was lower than that used in the Part I 
dual hit studies. However, both MG132 concentrations decreased astrocyte viability by 
approximately 50% in previously naïve cells. When we expressed the data from Fig 9A 
as a function of the 0 µM 2nd MG132 hit (i.e., all gray bars were expressed as a 
percentage of the adjacent black bars), the attenuation of the toxicity of the 2nd hit in 
previously stressed astrocytes became evident (Fig 9B). Consistent with the MG132 data, 
astrocytes surviving toxic concentrations of a different proteasome inhibitor, lactacystin, 
were also resistant to subsequent lactacystin insults (Fig 10). Lactacystin and MG132 
have distinct mechanisms of action, although both converge on the chymotrypsin-like 
activity of the proteasome particle and increase the cellular burden of misfolded proteins 
(D. H. Lee & Goldberg, 1998).  
 In order to determine whether the effect of the 1st MG132 hit on the 2nd MG132 
hit was long lasting, the duration between the 1st and 2nd hit was increased from 24h to 
48h (Fig 9D-F) and 96h (Fig 9G-I). Astrocytes that survived the toxic 1st hit remained 
protected against the 2nd hit for up to 96 hours. These findings suggest that the 1st hit does 
not elicit transient protective effects. In addition, we also examined the duration of the 
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protective effect by increasing the interval between the 2nd hit and the time of viability 
assay from 24 to 72h. As expected, astrocytes exposed to two severe proteotoxic insults 
remained viable for up to 72h after the 2nd hit (Fig 9J-L). All of these findings are 
consistent with the notion that stress-induced tolerance in this model is not fleeting in 
nature. 
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  Figure 9. Severe proteotoxic 
stress preconditions astrocytes 
against subsequent insults. A) 
Cortical astrocytes were treated 
with indicated concentrations of 
the proteasome inhibitor MG132 
one day after plating (1st hit) or an 
equal v/v of vehicle. Twenty-four 
hours later, astrocytes were 
challenged with a 2nd hit of 
MG132 (3.125 M) or vehicle. 
Astrocyte viability was assessed 
24h after the 2nd hit by counting 
viable Hoechst+ nuclei in blinded 
fashion.  B) Data in panel A were 
expressed as a percentage of each 
0 M 2nd MG132 hit group (i.e., 
each gray bar was expressed as a 
percentage of the adjacent black 
bar). C) Representative images of 
Hoechst-stained astrocyte nuclei 
from the groups shown in A. The 
interval between the 1st hit and the 
2nd hit was prolonged to 48h in D-
F and to 96h in G-I. E and H 
represent data in D and G, 
respectively, expressed as a 
percentage of the 0 M 2nd 
MG132 hit group. Representative 
Hoechst-stained nuclei are shown 
in F and I. J-K) The interval 
between the 2nd hit and the assay 
was extended to 72h. The data in 
panel J were expressed as a 
percentage of the 0 M 2nd 
MG132 hit group and presented in 
panel K. L) Representative 
images of Hoechst-stained nuclei 
from groups shown in J. * p ≤ 
0.05, ** p ≤ 0.01, *** p ≤ 0.001 
vs 0 M 2nd MG132 hit, + p ≤ 
0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 
vs 0 M 1st MG132 hit, two-way 
ANOVA followed by Bonferroni 
post hoc correction. 
Reprinted from “Astrocytes 
surviving severe stress can still 
protect neighboring neurons from 
proteotoxic stress,” by A. M. 
Gleixner, 2015, Molecular 
Neurobiology, Epub ahead of 
print. Copyright [2015] by A.M 
Gleixner. Reprinted with 
permission. 
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Figure 10. Lactacystin-mediated severe proteotoxic stress preconditions astrocytes 
against subsequent insults. A) Five days after plating, astrocytes were treated with various 
concentrations of lactacystin or an equivalent v/v of vehicle (phosphate buffered saline) as the 
1st hit. On the following day, the astrocytes were treated with vehicle or a 2nd hit of 
lactacystin at the indicated concentrations. Viability was assayed 24h after the 2nd hit by 
counting Hoechst-stained nuclei. B) Representative images of Hoechst-stained nuclei for 
experiments shown in panel A.  * p ≤ 0.05 vs 0 M 2nd lactacystin hit; + p ≤ 0.05, ++ p ≤ 
0.01, +++ p ≤ 0.001 vs 0 M 1st lactacystin hit, two-way ANOVA followed by Bonferroni 
post hoc correction Reprinted from “Astrocytes surviving severe stress can still protect 
neighboring neurons from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular 
Neurobiology, Epub ahead of print. Copyright [2015] by A.M Gleixner. Reprinted with 
permission. 
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Astrocytes surviving the 1st hit do not exhibit characteristics of apoptosis   
Hoechst or DAPI-stained cells undergoing apoptosis are often characterized by 
increased staining intensity and condensed nuclear area relative to non-apoptotic cells 
(Tone et al., 2007; Yu et al., 2002). Thus, we assessed nuclear area and staining intensity 
in astrocytes treated with 1st, 2nd, and dual MG132 hits in order to determine if the 1st hit 
left behind nuclear profiles exhibiting signs of cell death. The frequency distribution of 
the number of cells corresponding to specific nuclear sizes is shown in Figure 11A-C. No 
decrease in median nuclear size was found with the 1st, 2nd, or dual MG132 hits, 
supporting the view that most apoptotic cells had died and washed off the plate at the 
time of the viability assays. However, a slight decrease in average nuclear size was 
observed in astrocytes exposed to dual MG132 hits, even when excluding cells with 
nuclear areas less than 53 µm2 (Fig 11D & E). Representative images of Hoechst-stained 
nuclei are shown in Figure 11F. Similar to the nuclear area analysis, no shift in median 
nuclear staining intensity was observed in astrocytes treated with 1st, 2nd and dual MG132 
hits (Fig 11G-I). Furthermore, no change in average nuclear staining intensity with 1st, 
2nd, and dual MG132 hits was observed either. These findings suggest that cells 
undergoing dual hits show a slight decrease in nuclear area but not staining intensity, but 
that the effect size is very small. Most importantly, these measurements reveal that cells 
surviving the 1st hit alone have viable nuclei with no change in average nuclear size. 
 As mentioned above, cells undergoing apoptosis are often described as having 
shrunken nuclei with increased Hoechst staining intensity (Tone, et al., 2007). Therefore, 
we assessed the relationship between nuclear size and Hoechst-staining intensity in the 1st 
hit, 2nd hit, and both hit groups. According to the scatterplots, MG132 treatment 
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eliminated a population of cells with small brightly stained nuclei [nuclear size 50-150 
µm2 and nuclear staining intensity greater than 20 arbitrary units (A.U.) for the mean gray 
value measurements] (Fig 11L-O). Therefore, we compared the effect of MG132 on the 
small, brightly stained nuclei to the effect of MG132 on cells with large nuclei (larger 
than 150 µm2). MG132 eliminated a greater percentage of Hoechst-stained nuclei in the 
small, brightly stained nuclei group relative to the larger nuclei group (Fig 11P). These 
data are normalized to the vehicle group because the number of nuclei in the large nuclei 
group is significantly greater than the number of nuclei in the small, brightly stained 
nuclei group. The raw, untransformed data that show these differences are illustrated in 
Figure 12. Thus, small, brightly stained nuclei are most vulnerable to proteotoxic stress, 
as might be expected because they already show signs of injury. 
 Double-stranded DNA breaks are indicative of cells undergoing apoptosis. The 
TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) stain is a well-
established marker of apoptosis (Elmore, 2007; Gavrieli, Sherman, & Ben-Sasson, 1992). 
Terminal deoxynucleotidyl transferase incorporates fluorescently labeled dUTP onto the 
exposed 3’-OH ends of the double-stranded DNA breaks in apoptotic cells. We counted 
the number of TUNEL+ cells in our dual hit model in order to determine the number of 
cells undergoing apoptosis at the time that our viability assays were conducted. Less than 
10% of the total number of cells present at the time of fixation (24h after the 2nd hit) were 
TUNEL+ in the 2nd MG132 hit group (Fig 11Q). The 0.16 µM 1st MG132 hit did not elicit 
any increase in the number of TUNEL+ cells by itself in comparison to the 0 µM 1st 
MG132 hit. The 1st hit also did not change the number of TUNEL+ cells in response to 
the 2nd MG132 hit. Due to very low numbers of TUNEL+ cells, there was high inter-
53 
 
experimental variability of the data. Thus, we also expressed the number of TUNEL+ 
cells as a fold change over control values. Here we found that both naïve and stressed 
astrocytes showed a significant increase in TUNEL staining in response to the 2nd 
MG132 hit (Fig 11R). Representative images of TUNEL+ cells are displayed in Figure 
11S. It is noteworthy that the number of TUNEL+ profiles was low at the time of the 
assay, suggesting that we are mostly counting live cells at the time that our viability 
assays are conducted. Furthermore, our data confirm that the 1st hit does not increase the 
number of TUNEL+ profiles in response to the 2nd hit, suggesting that cell death is not 
enhanced despite a slight shrinkage of nuclear surface area in the dual hit group. In sum, 
these data are consistent with the analyses of nuclear size and Hoechst-staining intensity 
and demonstrate that the 1st hit does not increase vulnerability to the 2nd hit when 
measuring either live or dead cells because the fold change in TUNEL+ cells is similar 
between naïve and stressed cells. It is important to note that by far the majority of cells 
that we are counting in the dual hit group are not TUNEL+ and that they continue to 
survive for at least 72h after the 2nd hit is administered (see Figure 9J-L), suggesting that 
they are indeed survivors despite a slight decrease in average nuclear size. It is also 
important to note that the TUNEL stain labels small, dying cells that are excluded from 
our viable cell counts by the threshold function in ImageJ anyway. From the scatterplots 
in Figure 11O it is further evident that the dual hits kill the brightest, smallest cells (0-150 
microns in size) and that the majority of remaining cells are clustered around nuclear 
sizes of 150 to 300 microns instead of a wider spread from 0 to 400 microns in the 
untreated group (Figure 11L). The clustering of cells in the scatterplot data readily 
explain the small decrease in average nuclear size in the dual hit group Figure 11E and 
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the lack of change in median nuclear area in the dual hit group in Figure 11C. The 
clustering effect is also apparent in the shape of the dual hit histogram in Figure 11C. 
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Figure 11. See below for figure legend 
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Figure 11. Nuclear viability in stressed astrocytes. Astrocytes were treated with the indicated 
concentrations of MG132 24h (1st hit) and 48h (2nd hit) after plating. On the third day, astrocytes 
were stained with the nuclear marker Hoechst and analyzed by a blinded observer using ImageJ 
software. A-C) Frequency distributions of the number of nuclei corresponding to the indicated 
nuclear area. The vehicle-treated group is included on all three figures for comparison. D) Average 
nuclear size of all cellular profiles. E) Average size of all nuclei except those smaller than 53 µm2. 
F) Representative high-power image of Hoechst-stained nuclear profiles. G-I) Frequency 
distribution of the number of nuclei as a function of Hoechst nuclear staining intensity. The 
vehicle-treated group is included on all three figures for comparison. J) Average nuclear staining 
intensity of all cellular profiles. K) Average nuclear staining intensity of all profiles except cells 
with nuclei smaller than 53 µm2. L-O) Nuclear staining intensity as a function of nuclear size. P) 
Astrocytes were divided into two groups: those with small, bright nuclei (50-150 µm2; staining 
intensity greater than 20 arbitrary units for the mean gray value measurements) or large nuclei 
(greater than 150 µm2; all staining intensities). Raw data is presented in Figure 12. Q) Number of 
TUNEL+ cells relative to the total number of Hoechst+ nuclei. R) Data presented in panel Q were 
expressed as a function of the 0 M 2nd MG132 hit groups. S) Representative images of TUNEL 
staining. * p ≤ 0.05, ** p ≤ 0.01 vs 0 M 2nd MG132 hit; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 
vs 0 M 1st MG132 hit; ^ p ≤ 0.05, ^^ p ≤ 0.01 vs small, bright nuclei; two- or three-way 
ANOVA followed by Bonferroni post hoc correction. Reprinted from “Astrocytes surviving 
severe stress can still protect neighboring neurons from proteotoxic stress,” by A. M. Gleixner, 
2015, Molecular Neurobiology, Epub ahead of print. Copyright [2015] by A.M Gleixner. 
Reprinted with permission. 
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Figure 12. MG132 treatment is more lethal to small, bright nuclei 
than large nuclei. A) Hoechst-stained nuclei were categorized into 
two groups: those exhibiting small, brightly stained nuclei (50-150 
µm2 in size and staining intensity greater than 20 arbitrary units for 
the mean gray value measurements) or large nuclei (greater than 150 
µm2; all staining intensities). Raw counts of the numbers of nuclei per 
microscopic field of view (200× magnification) are shown here to 
supplement the transformed data in Figure 3P. * p ≤ 0.05, ** p ≤ 0.01 
vs 0 M 2nd MG132 hit; ++ p ≤ 0.01 vs vs 0 M 1st MG132 hit; ^^ p ≤ 
0.01, ^^^ p ≤ 0.001 vs small, bright nuclei, three-way ANOVA 
followed by Bonferroni post hoc correction. Reprinted from 
“Astrocytes surviving severe stress can still protect neighboring 
neurons from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular 
Neurobiology, Epub ahead of print. Copyright [2015] by A.M 
Gleixner. Reprinted with permission. 
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Severe proteotoxic stress increases the expression of multiple defensive proteins 
 As we had switched protocols, we reexamined ubiquitinated protein and Hsp70 
levels after dual hits in the new model in order to assess the effect of severe 
proteotoxicity on astrocytes. A significant increase in ubiquitinated proteins was 
observed 24h after the 1st MG132 hit, at the time of delivery of the 2nd hit (Fig 13A). 
These findings confirm that the 1st hit elicits proteotoxic stress. Forty-eight hours after the 
1st hit, there was no significant difference in the levels of ubiquitinated proteins between 
the 0 and 0.16 µM 1st MG132 hit groups, supporting the view that the increase in 
ubiquitinated proteins was transient. Furthermore, the 2nd MG132 hit elicited a significant 
increase in ubiquitinated proteins in both naïve and stressed astrocytes 24h later (Fig 
13B). Unlike in our initial studies (see Fig 4a), the two hits of MG132 were not 
synergistic in their impact on ubiquitinated protein levels, perhaps because the 
concentrations of MG132 were much lower in the new model. Nevertheless, these 
findings are still consistent with the hypothesis that previously stressed astrocytes are not 
simply refractory to the effects of MG132 and still respond to proteasomal inhibition by 
the 2nd hit with a dramatic increase in ubiquitin-conjugated proteins. The transient 
increase in ubiquitinated proteins after the 1st hit is also not consistent with the view that 
the MG132 survivors do not even take up the MG132 poison or are refractory to its 
effects. 
Next we examined heat shock protein levels after the 1st hit. Depending upon the 
heat shock protein examined, the 1st MG132 hit yielded varying effects on protein levels 
24h after treatment (Fig 13C-L). Some heat shock proteins, such as pHsp27 and Hsp70, 
were significantly upregulated 24h after the 1st MG132 hit. Trends towards increases in 
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Hsp40 (p = 0.093), HO1 (p = 0.058), and Hsc70 (p = 0.070) were also observed 24h after 
the 1st MG132 hit. However, several other defensive proteins were not altered by the 1st 
MG132 hit (DJ-1, Hsp27, Hsp90 and Hip). Similar to the ubiquitinated protein pattern, 
Hsp70 and HO1 were significantly increased by the 2nd MG132 hit in both naïve and 
stressed astrocytes (Fig 13M & N). These findings suggest that astrocytes can still mount 
defenses against subsequent proteotoxic insults despite prior exposure to severe stress. 
Another important finding is that there is an increase in Hsp70 24h after the 1st hit alone 
(Figure 13L) that wanes within 48h (or 24h after the 2nd hit in Figure 13M). Thus, the 1st 
hit elicits a transient rise in Hsp70 as shown with the ubiquitin data. This finding suggests 
that the 1st hit elicits active defenses in the cells that manage to survive and is not 
consistent with the view the 1st hit simply leaves behind cells that have higher expression 
of protective proteins to begin with and do not respond with any additional adaptive 
changes in response to MG132. In conclusion, our data show that stressed astrocytes that 
survive the 1st hit are not simply refractory to the MG132 poison and respond actively to 
proteotoxicity, otherwise there could not be a transient rise in Hsp70 
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Figure 13. MG132 increases protein misfolding stress and upregulates Hsp70 and HO1 
levels. Astrocytes were treated with indicated concentrations of MG132 (1st hit) and probed for 
a number of stress-sensitive proteins 24h later (A, C-L). Astrocytes were treated with single or 
dual hits of MG132 and assayed for levels of ubiquitinated proteins and heat shock proteins 
Hsp70 and HO1 24h after the 2nd hit (B, M-N). *** p ≤ 0.001 vs 0 M 2nd MG132 hit, + p ≤ 
0.05, ++ p ≤ 0.01 vs 0 M 1st MG132 hit, two-way ANOVA followed by Bonferroni post hoc 
correction for B, M, and N. The one-tailed, paired Student’s t-test was used for A, C-L. 
Reprinted from “Astrocytes surviving severe stress can still protect neighboring neurons from 
proteotoxic stress,” by A. M. Gleixner, 2015, Molecular Neurobiology, Epub ahead of print. 
Copyright [2015] by A.M Gleixner. Reprinted with permission. 
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Glutathione but not Hsp70 defenses are essential for stress tolerance in astrocytes 
 Thus far, we showed that the 1st MG132 hit upregulates Hsp70 levels at 24h, at 
the time of delivery of the 2nd MG132 hit. Hsp70 overexpression has been shown to 
increase glutathione peroxidase and reductase activity (Guo, et al., 2007), and our 
previous study had shown that glutathione is essential for stress tolerance in astrocytes 
(Titler, et al., 2013). Therefore, we hypothesized that Hsp70 may contribute to the 
protective effects of glutathione in stressed astrocytes. Thus, we inhibited Hsp70 and 
glutathione defenses both individually and together. Our results were not consistent with 
the hypothesis that Hsp70 mediates tolerance in our model because a pharmacological 
inhibitor of Hsp70, VER155008, did not alter the resistance of previously stressed 
astrocytes to subsequent proteotoxic insults (Fig 14A-C). However, as observed 
previously, glutathione synthesis inhibition by BSO did attenuate resistance to the 2nd 
MG132 hit in previously stressed astrocytes. Simultaneous inhibition of Hsp70 activity 
and glutathione synthesis elicited a significant decrease in basal viability (as observed 
with VER155008 alone) and increased susceptibility of previously stressed astrocytes to 
a 2nd MG132 hit (as observed with BSO alone; Fig 14A). As expected, when the data are 
expressed as a function of the 0 µM 2nd MG132 hit group, they reveal increased 
susceptibility of previously stressed astrocytes to the 2nd hit in the presence of BSO but 
not VER155008 (Fig 14B). Figure 14C shows representative images of Hoechst-stained 
cells corresponding to the data presented in Figure 14A. These findings reveal that 
glutathione loss unmasks the toxic impact of the 2nd hit and are not consistent with the 
hypothesis that the astrocytes surviving the 1st hit of MG132 are simply refractory to any 
of its effects. In other words, if there were no defenses against MG132 in the surviving 
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astrocytes, they would not become vulnerable to MG132 upon loss of glutathione 
defenses. 
 Because glutathione was an important mediator of stress tolerance in our model, 
we measured total glutathione levels and found that the 2nd MG132 hit significantly 
increased glutathione (Fig 14D). There was also a trend towards an increase in the 1st hit 
group (p = 0.059). Total glutathione levels were even higher when Hsp70 activity was 
inhibited by VER155008. Therefore, Hsp70 may not be a positive regulator of 
glutathione synthesis in our model, but may reduce the need for this antioxidant. As 
expected, BSO attenuated the effect of MG132 on total glutathione levels (Fig 14D & E). 
The assay for total glutathione levels measures both the reduced and oxidized forms of 
the thiol tripeptide. However, glutathione exists primarily in the reduced state (Owen & 
Butterfield, 2010), which suggests that total glutathione measures are likely to coincide 
with the reduced glutathione levels. To confirm this, reduced glutathione levels were 
measured by the GSH-Glo assay. Twenty-four hours after delivery of the 1st MG132 hit 
(or at the same time point as the 2nd hit delivery) reduced glutathione was significantly 
increased intracellularly but not in the extracellular space (Fig 14F & G, respectively). 
Forty-eight hours after the 1st hit, the 1st and 2nd MG132 hits alone significantly increased 
intracellular reduced glutathione levels. No additional increase in reduced glutathione 
was observed in the dual hit group (Fig 14H). These results are consistent with the view 
that feedback inhibition on the rate limiting enzyme glutamate cysteine ligase prevents 
any additional rise in glutathione levels in response to dual hits (C. S. Huang, Chang, 
Anderson, & Meister, 1993). No additional increase may be evident after the 2nd MG132 
hit because the 1st hit has already upregulated those defenses and there is no further need 
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for a stress-induced rise in antioxidant defenses. The pattern of glutathione measurements 
was similar for the In-Cell Western and GSH-Glo assays, as expected, suggesting that 
most glutathione is in the reduced form. 
In order to understand how glutathione defenses may be boosted in stressed cells, 
glutamate cysteine ligase levels were examined by Western blot analysis. Glutamate 
cysteine ligase is comprised of two subunits: the catalytic and modifier subunits. 
Glutamate cysteine ligase modifier subunit (GCLM) levels were elevated 24h after the 1st 
MG132 hit (Fig 14I). However, no significant increase was observed in glutamate 
cysteine ligase catalytic subunit levels (Fig 15A). GCLM has been shown to increase the 
catalytic efficiency of GCLC (Franklin, et al., 2009). Therefore, higher GCLM levels 
may be sufficient to permit an increase in glutathione synthesis. We also measured a third 
glutathione enzyme, glutathione S-transferase, which eliminates xenobiotics. The class of 
glutathione S-transferase enzymes is divided according to the composition of their N-
terminal domain (Mazzetti, et al., 2015). Glutathione S-transferase π and µ have both 
been identified in astrocytes (Abramovitz et al., 1988; Cammer & Zhang, 1993; Johnson, 
el Barbary, Kornguth, Brugge, & Siegel, 1993). Therefore, we assessed the effect of 1st 
MG132 hit on glutathione S-transferase π and µ. The 1st MG132 hit significantly raises 
glutathione S-transferase µ such that it is upregulated at the time of the 2nd MG132 hit 
(Fig 14J). However, no significant increase in glutathione S-transferase π with the 1st 
MG132 hit was observed (Fig 15B). In summary, glutamate cysteine ligase modifier 
subunit and glutathione S-transferase µ may promote glutathione defenses in our model. 
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Figure 14. See below for figure legend 
65 
 
  
Figure 14. Inhibition of glutathione synthesis but not Hsp70/Hsc70 activity abolishes stress-induced 
protection against the 2nd MG132 hit. A) Cortical astrocytes were treated with the indicated 
concentrations of MG132 in the absence or presence of the Hsp70/Hsc70 inhibitor VER155008 and 
glutathione synthesis inhibitor buthionine sulfoximine (BSO). Viable Hoechst+ nuclei were quantified 
24h after the 2nd hit to measure viability. B) Data from panel A were expressed as a percentage of the 0 
M 2nd MG132 hit groups (i.e. all gray bars were expressed as a percentage of the adjacent black bars). 
C) Representative images of Hoechst-stained nuclei from data shown in panel A.  D) Total glutathione 
levels were measured 24h after the 2nd MG132 hit by the In-Cell Western technique and expressed as a 
function of the corresponding number of Hoechst+ nuclei to control for differences in cell density. E) 
Representative image of total glutathione In-Cell Western. F-H) Reduced glutathione levels were 
measured intracellularly and in the extracellular media by the Glutathione-Glo assay and luminescence 
was expressed as a function of the number of Hoechst+ nuclei on parallel plates. All glutathione assays in 
F-H were performed 24h after the final MG132 hit. I-J) Western blot analysis of glutamate cysteine 
ligase modifier subunit (GCLM) and glutathione S-transferase µ (GST-µ) in lysates collected 24h after 
the 1st MG132 hit. K) Astrocytes were treated with single and dual hits of MG132 in the absence or 
presence of BSO and ATP levels were measured by the CellTiter-Glo assay 24h after the 2nd MG132 hit. 
ATP levels are expressed as a function of Hoechst+ cell numbers on parallel plates. * p ≤ 0.05, ** p ≤ 
0.01, *** p ≤ 0.001 vs 0 M 2nd MG132 hit; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 vs 0 M 1st MG132 
hit; ^ p ≤ 0.05, ^^ p ≤ 0.01 vs 0 M VER155008 and/or 0 µM BSO, two- or three-way ANOVA followed 
by Bonferroni post hoc correction. For F-G and I-J, the two-tailed paired Student’s t test was employed. 
Reprinted from “Astrocytes surviving severe stress can still protect neighboring neurons from proteotoxic 
stress,” by A. M. Gleixner, 2015, Molecular Neurobiology, Epub ahead of print. Copyright [2015] by 
A.M Gleixner. Reprinted with permission. 
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A B 
Figure 15. Impact of 1st hit on glutathione-related enzymes. Astrocytes were treated with 
the 1st MG132 hit or vehicle and the following glutathione-related proteins were measured 
in lysates collected 24h later: A) glutamate cysteine ligase catalytic subunit (GCLC), B) 
glutathione S-transferase π (GST-π). No significant difference was determined with the two-
tailed paired Student’s t test. Reprinted from “Astrocytes surviving severe stress can still 
protect neighboring neurons from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular 
Neurobiology, Epub ahead of print. Copyright [2015] by A.M Gleixner. Reprinted with 
permission. 
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Glutathione synthesis inhibition increases ATP levels in severely stressed astrocytes 
 ATP is important for fueling defensive responses in cells, and supplies energy for 
glutathione synthesis and heat shock protein activity (Bukau & Horwich, 1998; S. C. Lu, 
2009; Mayer & Bukau, 2005). Therefore, we measured ATP levels in our model. ATP 
levels were increased in astrocytes treated with the 1st, 2nd, and dual MG132 hits (Fig 
14K). The pattern in Figure 14K appears different from the pattern in Figure 3a in our 
previous model because we expressed ATP as a function of cell numbers. The data were 
expressed in this manner because Figure 3a does not take into consideration changes in 
astrocyte numbers; ATP loss might therefore mean loss of cell numbers, a drop in ATP 
output per cell, or both. BSO promoted a large increase in ATP levels in the dual hit 
group. Despite this increase in ATP, previously stressed astrocytes were susceptible to 
the 2nd MG132 hit in the presence of BSO, suggesting that the increase in ATP was not 
sufficient for protecting astrocytes. On the other hand, it is also possible that in the 
absence of the BSO-mediated rise in ATP, the stressed astrocytes would have been all the 
more vulnerable to MG132. 
System xc
- may not mediate protection in severely stressed astrocytes 
 Cysteine availability is often the rate-limiting component of glutathione synthesis 
and is determined partly by the system xc
- glutamate/cysteine antiporter (Bannai & 
Kitamura, 1980; Jackman, Melchior, Hewett, & Hewett, 2012; Sato et al., 2002). Thus, 
we tested the hypothesis that system xc
- would contribute to the stress-induced tolerance 
in this model. However, LY367385, a system xc
- and metabotropic glutamate receptor 
inhibitor (mGluR1), did not attenuate the resistance of previously stressed astrocytes to 
subsequent insults. To control for potential off-target effects of LY367385, YM298198, a 
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specific mGluR1 inhibitor, was also used. YM298198 did not attenuate the tolerance of 
previously stressed astrocytes towards subsequent MG132 insults, as expected (Fig 16A 
& B). Therefore, system xc
- may not contribute to glutathione-mediated protection of 
stressed astrocytes against subsequent proteotoxic insults. Further studies are nevertheless 
warranted, because of the possibility that both inhibitors only acted on mGluR1. 
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Figure 16. System xc- is not essential for resilience in severely 
stressed astrocytes. Cortical astrocytes were treated with the indicated 
1st and 2nd MG132 hit in the absence and presence of pharmacological 
inhibitors LY367385 and YM298198. A) Viability was assessed by 
blinded cell counts of Hoechst+ nuclei. B) Representative images of 
Hoechst-stained nuclei * p ≤ 0.05, ** p ≤ 0.01 vs 0 M 2nd MG132 hit, 
++ p ≤ 0.01, vs 0 M 1st MG132 hit three-way ANOVA followed by 
Bonferroni post hoc correction. Reprinted from “Astrocytes surviving 
severe stress can still protect neighboring neurons from proteotoxic 
stress,” by A. M. Gleixner, 2015, Molecular Neurobiology, Epub ahead 
of print. Copyright [2015] by A.M Gleixner. Reprinted with permission. 
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Heme oxygenase 1 activity is not essential for stress tolerance in astrocytes  
 As mentioned above, HO1 is a highly stress responsive protein that prevents cell 
death in response to oxidative injury (Schipper, et al., 2009). Furthermore, oxidative 
stress can be propagated by proteasome inhibition (Maharjan, Oku, Tsuda, Hoseki, & 
Sakai, 2014). Thus, we hypothesized that HO1 also contributes to the stress-induced 
tolerance in our model. As described above, the 1st MG132 hit elicited a trend towards an 
increase in HO1 protein levels (see Fig 13E). A competitive inhibitor of HO1 activity, tin 
protoporphyrin IX, did not alter the effect of MG132 on astrocytes in the dual hit model 
(Fig 17A & B). Pilot data show that the inhibitor does reduce HO1 activity (data not 
shown). Therefore, HO1 may not be responsible for the stress-induced protection in our 
model, although further studies to verify the efficacy of the HO1 inhibitor are in order. 
  
71 
 
  
Figure 17. Stressed astrocytes can resist dual hits despite HO1 inhibition. A) Astrocytes were 
treated with the 1st and 2nd MG132 hits 24h apart in the absence or presence of the heme oxygenase 
1 inhibitor SnPPx. Viability was assayed  24h after the 2nd hit. B) Representative images of Hoechst 
stained nuclei. * p ≤ 0.05, *** p ≤ 0.001 vs 0 M 2nd MG132 hit, + p ≤ 0.05, +++ p ≤ 0.001 vs 0 M 
1st MG132 hit, two-way ANOVA followed by Bonferroni post hoc correction. Reprinted from 
“Astrocytes surviving severe stress can still protect neighboring neurons from proteotoxic stress,” 
by A. M. Gleixner, 2015, Molecular Neurobiology, Epub ahead of print. Copyright [2015] by A.M 
Gleixner. Reprinted with permission. 
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Severely stressed astrocytes can still blunt proteotoxic cell death in neurons, even in the 
absence of glutathione and Hsp70/Hsc70 defenses 
 As shown above, glutathione synthesis is essential for protecting stressed 
astrocytes from subsequent proteotoxic insults. Astrocytes are known to provide 
glutathione precursors for neighboring neurons, which may prevent neuronal death 
during stress exposure (Dringen, et al., 2000; Dringen, et al., 1999). Therefore, we 
investigated whether severely stressed astrocytes can decrease proteotoxic stress in 
neighboring neurons and whether glutathione synthesis is essential for this effect. 
Neuron-astrocyte co-cultures were developed to answer this question and were conducted 
in collaboration with Dr. Jessica Posimo. Astrocytes were stressed with a 1st MG132 hit 
and the MG132 was then removed before neurons were plated in direct contact with the 
glial cells. The neuron-astrocyte contact co-cultures were then administered a 2nd MG132 
hit (2nd hit in reference to astrocytes). Neuron viability was measured by In-Cell Western 
analysis for the neuronal marker MAP2 (Caceres, Banker, Steward, Binder, & Payne, 
1984; Posimo, et al., 2014). Other studies have verified that the MAP2 In-Cell Western 
assay is a sensitive measure of neuronal viability (Posimo, et al., 2014). Primary neurons 
plated alone were highly susceptible to MG132 (Fig 18A & B). There was a trend 
towards neuroprotection against MG132 in the presence of unstressed astrocytes 
(p=0.067) (Fig 18A). In contrast, the severely stressed astrocytes attenuated neuronal 
death in response to the 2nd MG132 hit in a statistically significant manner. Surprisingly, 
inhibition of glutathione synthesis by BSO did not alter the effect of MG132 toxicity on 
neurons or the protective effects of astrocytes on neuronal viability. In order to verify that 
BSO was eliciting the expected decrease in glutathione, glutathione levels were measured 
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in the neuron-astrocyte co-cultures. The results show that 1) the presence of astrocytes 
significantly increased overall glutathione levels, 2) the 2nd MG132 hit significantly 
increased glutathione levels in a concentration-dependent manner, and 3) BSO abolished 
these effects (Fig 18C-E). These findings indicate that stressed co-cultures increase 
glutathione synthesis. We conclude that glutathione is not essential for astrocyte-
mediated protection of neurons from proteotoxicity although it is essential for protection 
of previously stressed astrocytes from subsequent insults. 
 Finally, we measured GFAP levels in co-cultures treated with BSO and MG132, 
as GFAP is a phenotypic marker of astrocytes. Some GFAP was detected in the neuron-
only group, because our primary neuronal cultures are derived from postnatal day 1-2 rat 
pups (a time at which astrocyte births peak) and contain 9.5% astrocytic cells (F. D. 
Miller & Gauthier, 2007). As expected, GFAP levels were dramatically higher in the co-
culture groups (Fig 18F & G). It is worth noting here that GFAP levels are not always in 
proportion to the number of cells because GFAP is a reactive stress marker. Therefore, 
we cannot use GFAP in an In-Cell Western analysis as a measure of astrocyte numbers. 
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Figure 18. Severely stressed astrocytes 
can protect neurons from proteotoxic 
stress.  A) Astrocytes were treated with 
the 1st MG132 hit 24h prior to 
introduction of neocortical neurons, in 
the absence or presence of the 
glutathione synthesis inhibitor 
buthionine sulfoximine (BSO). Two 
days after the introduction of neurons, 
the neuron/astrocyte co-cultures were 
treated with MG132 as a 2nd hit in the 
absence or presence of BSO.  Two days 
after the 2nd hit, neuronal viability was 
measured by the In-Cell Western assay 
for the specific neuronal marker MAP2. 
B) Representative image of MAP2 In-
Cell Western. C) Changes in glutathione 
levels were measured by In-Cell 
Western analyses and expressed as a 
function of the infrared nuclear stain 
DRAQ5. Representative images of 
glutathione immunostaining (D) and 
DRAQ5 levels (E). F) The astrocytic 
marker GFAP was measured by In-Cell 
Western analysis in neuron/astrocyte co-
cultures 48h after the 2nd MG132 hit in 
the absence or presence of BSO. G) 
Representative image of GFAP In-Cell 
Western. ** p ≤ 0.01, *** p ≤ 0.001 vs 0 
M 2nd MG132 hit, + p ≤ 0.05, ++ p ≤ 
0.01, +++ p ≤ 0.001 vs neurons, ^ p ≤ 
0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 vs 0 M 
BSO, three-way ANOVA followed by 
Bonferroni post hoc correction. 
Reprinted from “Astrocytes surviving 
severe stress can still protect 
neighboring neurons from proteotoxic 
stress,” by A. M. Gleixner, 
2015, Molecular Neurobiology, Epub 
ahead of print. Copyright [2015] by 
A.M Gleixner. Reprinted with 
permission. 
75 
 
Astrocytes robustly protect neurons against the synergistic toxicity of proteasome and 
Hsp70 inhibition  
 Although stressed astrocytes do not rely on Hsp70 activity for protection against 
subsequent proteotoxic insults, Hsp70 may be released from astrocytes via exosomes in 
order to protect neighboring cells, such as neurons, from proteotoxicity (Lancaster & 
Febbraio, 2005; Taylor, et al., 2007; Zhan et al., 2009). Therefore, we tested the 
hypothesis that the Hsp70 inhibitor VER155008 would attenuate the neuroprotection 
afforded by astrocytes. As before, MG132 significantly decreased neuron viability in the 
neuron-only group. Furthermore, naïve and previously stressed astrocytes both attenuated 
MG132 toxicity in neurons. Significant protection against MG132 toxicity in neurons by 
naïve astrocytes may have been observed in these experiments and not the previous 
experiments in Figure 18 because MG132 was less toxic in the later experiments. The 
variability in MG132 toxicity may be attributed to differences in MG132 stock solutions 
or the quality of the neuronal cultures. However, all the trends in the two sets of data are 
identical and speak to the reproducibility of the neuroprotective properties of stressed 
astrocytes. In the neuron-only group, Hsp70 inhibition by VER155008 and proteasome 
inhibition by MG132 elicited a synergistic decrease in neuron viability (Fig 19A-C). 
Naïve and previously stressed astrocytes significantly protected neurons against the 
synergistic toxicity of MG132 and VER155008, an effect that is also evident when the 
data are expressed as a percentage of the 0 µM VER155008 group (Figure 19B). As 
observed in the earlier co-culture studies, GFAP levels were higher in the neuron-
astrocyte co-culture group, and some GFAP was detected in the neuron-only group (Fig 
19D & E).  
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Figure 19. Stressed astrocytes prevent the synergistic toxicity of proteasome and Hsp70/Hsc70 
inhibitors. A) Astrocytes were treated with the 1st MG132 hit 24h prior to introduction of 
neocortical neurons, in the absence or presence of the Hsp70/Hsc70 inhibitor VER155008. Two 
days after the introduction of neurons, the neuron/astrocyte co-cultures were treated with MG132 as 
a 2nd hit in the absence or presence of VER155008. Two days after the 2nd hit, neuronal viability was 
measured by the In-Cell Western assay for MAP2. B) Data from panel A were expressed as a 
percentage of the 0 M VER155008 groups to illustrate the exacerbation of MG132 toxicity by 
VER155008. C) Representative image of MAP2 In-Cell Western. D) The astrocytic marker glial 
fibrillary acidic protein (GFAP) was analyzed by In-Cell Western analyses 48h after the 2nd hit in 
the same neuron/glia co-cultures as shown in panels A-C. E) Representative image of GFAP In-Cell 
Western. * p ≤ 0.05,  *** p ≤ 0.001 vs 0 M 2nd MG132 hit, + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 
vs neurons, ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 vs 0 M VER155008, three-way ANOVA 
followed by Bonferroni post hoc correction. Reprinted from “Astrocytes surviving severe stress can 
still protect neighboring neurons from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular 
Neurobiology, Epub ahead of print. Copyright [2015] by A.M Gleixner. Reprinted with permission. 
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Astrocytes-mediated neuroprotection is dependent upon physical contacts  
 Astrocytes are known to support neurons by providing metabolic precursors, 
antioxidants, and trophic factors (Allen & Barres, 2009). Thus, we sought to determine 
whether astrocytes release a diffusible factor in order to protect neurons against 
proteotoxicity using astrocyte-conditioned media (ACM). First, astrocytes were treated 
with MG132 for 24h. The ACM was then added to neuron growth media (at a dilution of 
1:1) in primary neuron cultures. Neurons with or without ACM were then treated with an 
MG132 insult (2nd MG132 hit) and neuron viability was measured 24h later. As expected, 
neuron viability was decreased by the 2nd MG132 hit, but conditioned media from either 
stressed or unstressed astrocytes completely failed to alter the effect of MG132 on neuron 
viability (Fig 20A & B). Because the diffusible factors may have been too dilute with our 
protocol, ACM was also concentrated by centrifugation and delivered to neurons at a 10× 
concentration. However, concentrated ACM also did not alter the effect of MG132 on 
neuron viability either (data not shown).   
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Figure 20. Stressed neurons are not protected from 
proteotoxicity by astrocyte-conditioned media. A) The 1st 
MG132 hit or an equivalent v/v of vehicle was added for 24h to 
wells in the presence of astrocytes (conditioned media) or in 
their absence (unconditioned media). Conditioned and 
unconditioned media (still containing 1st hit MG132 or vehicle) 
were then delivered to neocortical neurons by diluting them 1:1 
in neuron media. The 2nd MG132 hit was administered at the 
time of media transfer. Neuronal viability was measured by the 
In-Cell Western assay for MAP2 48h after media transfer.  B) 
Representative image of MAP2 In-Cell Western. *** p ≤ 0.001 
vs 0 M 2nd MG132 hit, three-way ANOVA followed by 
Bonferroni post hoc correction Reprinted from “Astrocytes 
surviving severe stress can still protect neighboring neurons 
from proteotoxic stress,” by A. M. Gleixner, 2015, Molecular 
Neurobiology, Epub ahead of print. Copyright [2015] by A.M 
Gleixner. Reprinted with permission. 
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3.2 N-acetyl cysteine-mediated protection of astrocytes against proteotoxicity is 
dependent upon heat shock protein activity 
N-acetyl cysteine attenuates proteotoxicity in astrocytes 
 N-acetyl cysteine (NAC) has shown beneficial effects in multiple neurological 
conditions (Adair, et al., 2001; Berk, Copolov, Dean, Lu, Jeavons, Schapkaitz, Anderson-
Hunt, Judd, et al., 2008; Berk, Copolov, Dean, Lu, Jeavons, Schapkaitz, Anderson-Hunt, 
& Bush, 2008; M. E. Hoffer, et al., 2013). These therapeutic effects of NAC are thought 
to be mediated by antioxidant effects on neurons. As astrocytes are known to support 
neurons, it is also important to protect astrocytes from protein misfolding stress in 
neurological conditions so that they can continue to promote neuronal health. Therefore, 
we sought to determine the therapeutic potential of NAC in astrocytes exposed to 
proteotoxicity. First, we hypothesized that NAC would prevent MG132 toxicity in 
cortical astrocytes. Consistent with this expectation, NAC decreased the MG132-induced 
loss of Hoechst+ nuclei in a concentration-dependent manner (Fig 21A). Representative 
images of Hoechst-stained nuclei and the preservation of cellular morphology by NAC 
are presented in Figure 21B and C.  
  
80 
 
  
Figure 21. NAC protects astrocytes from MG132 toxicity. Cortical astrocytes were treated with 
vehicle (DMSO) or a range of MG132 concentrations in the presence of 3 mM NAC or vehicle 
(H2O, equivalent v/v). A) Viability was determined 48h later by blinded counts of Hoechst+ nuclei. 
B) Representative images of Hoechst+ nuclei. C) Representative images of astrocytes stained for 
S100β (green), glial fibrillary acidic protein (GFAP, red), and Hoechst (blue). Shown are the mean ± 
SEM of 3 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 versus 0 µM MG132; ++ 
p ≤ 0.01, +++ p ≤ 0.001 versus 0 mM NAC, two-way ANOVA followed by Bonferroni post hoc test. 
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NAC protects astrocytes independent of glutathione synthesis  
 As mentioned above, proteotoxic stress is often associated with oxidative stress. 
NAC is known to be a glutathione precursor and can also have direct antioxidant effects 
(Aruoma, Halliwell, Hoey, & Butler, 1989; E. Hoffer, Baum, Tabak, & Taitelman, 1996). 
Therefore, we sought to determine whether NAC protects astrocytes from MG132 
toxicity through a glutathione-dependent mechanism. MG132 increased total glutathione 
levels in a concentration-dependent manner and NAC unexpectedly attenuated this effect 
(Fig 22A & B). These data suggest that NAC protects astrocytes in a glutathione-
independent manner. In order to test this directly, we used the glutathione synthesis 
inhibitor BSO to decrease glutathione levels (Fig 22C &D).  As outlined above, the In-
Cell Western assay measures total glutathione levels, which include both the reduced and 
oxidized forms. The reduced form of glutathione is important for defense against 
oxidative stress. Thus, reduced glutathione levels were also measured in our model. 
MG132 significantly increased intracellular levels of reduced glutathione, and NAC 
attenuated the rise in glutathione in response to MG132, consistent with the 
abovementioned results of the In-Cell Western assay. Reduced glutathione levels were 
slightly increased in the presence of NAC in cells not exposed to MG132 (Fig 22E). No 
significant changes in reduced glutathione levels were observed in the extracellular space 
with the exception of a BSO-induced decrease in reduced glutathione in the NAC-treated 
group (Fig 22F). These results suggest that MG132 elicits a stress-induced increase in 
glutathione synthesis but that there may be less need for this compensatory stress 
response in the presence of NAC. 
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 Next, we tested whether glutathione synthesis is essential for NAC-mediated 
protection against MG132 toxicity in astrocytes. Glutathione synthesis was inhibited by 
BSO and astrocyte viability was measured by counting the number of Hoechst+ 
astrocytes. BSO did not abolish or even attenuate the protective effects of NAC (Fig 22G 
& H). These findings suggest that glutathione synthesis is not essential for NAC-
mediated protection against MG132 toxicity.  
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Figure 22. NAC protects astrocytes against MG132 independent of glutathione synthesis. 
Cortical astrocytes were treated with the indicated MG132 concentrations in the presence of NAC 
(3 mM) or the equivalent v/v of vehicle. A) Total glutathione levels were measured 48h later by 
the fluorescent In-Cell Western assay. Total glutathione levels are expressed as a function of the 
number of Hoechst+ cell numbers. B) Representative total glutathione In-Cell Western image for 
data presented in panel A. C) Total glutathione levels as a function of the number of Hoechst+ 
nuclei in the absence and presence of glutathione synthesis inhibitor, buthionine sulfoximine 
(BSO). D) Representative In-Cell Western image of total glutathione levels for data presented in 
panel C. Intracellular (E) and extracellular (F) reduced glutathione levels in the absence or 
presence of BSO were measured by the luminescent GSH-Glo assay. G) Blinded counts of the 
number of Hoechst+ nuclei in the absence or presence of BSO. H) Representative images of 
Hoechst+ nuclei for the data shown in panel G. Shown are the mean and SEM of 3-5 independent 
experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001  versus 0 µM MG132; + p ≤ 0.05, ++ p ≤ 0.01, 
+++ p ≤ 0.01  versus 0 mM NAC; ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001  versus 0 µM BSO, two- 
or three-way ANOVA followed by Bonferroni post hoc correction. 
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Cysteine thiols protect astrocytes against protein-misfolding stress  
 We had shown in Figure 22 that NAC did not protect against MG132 toxicity by 
increasing glutathione levels. In order to elucidate the mechanism underlying NAC-
mediated glioprotection, the therapeutic potential of two cysteine isoforms was tested. 
Cysteine can exist in the L- or D- conformation, with L-cysteine being the biologically 
active form of cysteine that can be incorporated into glutathione whereas D-cysteine 
cannot be directly incorporated into glutathione (Corcoran & Wong, 1986). Both forms of 
cysteine contain a thiol group, which is known to attenuate oxidative stress (Requejo, 
Hurd, Costa, & Murphy, 2010). Figure 23 illustrates that both D- and L-cysteine 
(subpanels A & B and C & D, respectively) protect astrocytes against MG132 toxicity.  
D-amino acids may be converted to L-amino acids by D-amino acid oxidase 
(Friedman & Levin, 2012; Sacchi, et al., 2008). Therefore, in order test whether D-
cysteine was protective due to conversion to L-cysteine, D-amino acid oxidase was 
inhibited with sodium benzoate (Gong et al., 2011; Van den Berghe-Snorek & 
Stankovich, 1985). Sodium benzoate did not affect the protection against MG132 toxicity 
by D- and L-cysteine (Fig 23E-H). Therefore, we speculate that protection against 
MG132 toxicity by all three cysteines (NAC, L-cysteine, and D-cysteine) may occur 
through the thiol that they all have in common. 
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Figure 23. D-cysteine and L-cysteine protect astrocytes against MG132 toxicity. Cortical 
astrocytes were treated with MG132 or vehicle in the presence of D-cysteine (A, B) and L-
cysteine (C, D) or vehicle. (E-H) Sodium benzoate was delivered in conjunction with D- and L-
cysteine to inhibit the conversion of D- to L-cysteine by D-amino acid oxidase. Viability was 
measured 48h later by blinded counts of the number of Hoechst+ nuclei. Representative images of 
Hoechst+ nuclei are illustrated. Shown are the mean and SEM of 3-6 independent experiments. ** 
p ≤ 0.01, *** p ≤ 0.001 versus 0 µM MG132; + p ≤ 0.05, ++ p ≤ 0.01, +++ p ≤ 0.001 vs 0 mM D-
cysteine or L-cysteine, two- or three-way ANOVA followed by Bonferroni post hoc test. 
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NAC attenuates the stress-induced upregulation of several heat shock proteins  
 We previously showed that NAC protects neuroblastoma cells in a heat shock 
protein-dependent manner (Jiang, et al., 2013). Thus, here we examined heat shock 
proteins in MG132- and NAC-treated astrocytes. Proteotoxic stress elicited a significant 
increase in multiple heat shock proteins but NAC attenuated this effect, in contrast with 
the findings in neuroblastoma cells (Fig 24). Although NAC attenuated the rise in Hsp70 
and HO1 under proteotoxic conditions, these heat shock proteins remain elevated relative 
to the 0 µM MG132 group in the presence of NAC (Fig 24A & C, respectively). Thus, 
these heat shock proteins may nevertheless contribute to the protective effects of NAC.  
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Figure 24. NAC attenuates the MG132-induced increase in heat shock proteins in astrocytes. 
Cortical astrocytes were treated with MG132 or vehicle in the presence or absence of NAC. Lysates 
were collected 24h later and heat shock proteins were measured by Western blot analysis. 
Representative Western blot images are included below each graph. A) Heat shock protein 70 
(Hsp70), B) heat shock cognate 70 (Hsc70), C) heme oxygenase 1 (HO1 or heat shock protein 32), D) 
heat shock protein 25 (Hsp25), E & F) phosphorylated Hsp25, G) heat shock protein 40 (Hsp40), and 
H) heat shock protein 90 (Hsp90). Protein levels are expressed as a function of the loading controls β-
actin, GAPDH or α-tubulin, depending upon the species of the antibody for the protein of interest and 
its MW. Shown are the mean and SEM of 3-5 independent experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p 
≤ 0.001  versus 0 µM MG132; + p ≤ 0.05, +++ p ≤ 0.01 versus 0 mM NAC, two-way ANOVA 
followed by Bonferroni post hoc test. 
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Hsp70 and HO1 activity are essential for NAC-mediated protection of astrocytes against 
proteotoxicity 
 As mentioned above, Hsp70 is important for defending against proteotoxicity and 
is increased in response to proteasome inhibition by MG132. Geldanamycin is an Hsp90 
inhibitor and is known to increase Hsp70 levels as a result of Hsp90 inhibition (McLean, 
Klucken, Shin, & Hyman, 2004; Shen, He, Wang, Huang, & Chen, 2005). Thus we tested 
the hypothesis that geldanamycin protects astrocytes against MG132 toxicity as proof of 
principle. As expected, we found that geldanamycin abolished MG132 toxicity in 
astrocytes (Fig 25A & B).  
In Figure 24, we had shown that NAC attenuated the MG132-induced rise in 
Hsp70. However, Hsp70 levels were still significantly higher in the MG132-treated group 
in the presence of NAC relative to cells not exposed to MG132, suggesting that Hsp70 
may still contribute to the protective effects of NAC. Therefore, we next tested the 
hypothesis that Hsp70 inhibitors would abolish the protective effects of NAC. Consistent 
with this hypothesis, the protective effects of NAC were attenuated by three independent 
Hsp70 pharmacological inhibitors with unique mechanisms of action: VER155008 (Fig 
26A-C), pifithrin-µ (Fig 26D-F), and MAL3-101 (Fig 26G & H). These findings strongly 
suggest that Hsp70 activity may be an important factor in the protective effects of NAC. 
Inhibition of Hsp70 by itself did not increase the susceptibility of astrocytes to MG132 in 
the absence of NAC. Therefore, it is possible that other heat shock proteins compensate 
for Hsp70 inhibition in this group and prevent any additional decrease in viability with 
MG132.  
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We previously observed that NAC elicited a trend towards an increase in HO1 in 
MG132-treated neuroblastoma cells (Jiang, et al., 2013). Thus, here we tested the 
hypothesis that inhibition of HO1 would also attenuate NAC-mediated protection. 
Consistent with this hypothesis, inhibition of HO1 activity by SnPPx attenuated the 
protective effects of NAC in astrocytes (Fig 27A & B). Therefore, heat shock protein 
activity (Hsp32 or HO1 and Hsp70) appears to contribute to the NAC-mediated 
protection against MG132 toxicity (Fig 26 & 27).  
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Figure 25. Geldanamycin protects against MG132 toxicity in astrocytes Cortical astrocytes were 
treated with 0.2 µM MG132 and geldanamycin (312.5, 625, 1250 pM). A) Astrocyte viability was 
determined by blinded counts of Hoechst+ nuclei B) Representative image of Hoechst-stained nuclei. ** 
p ≤ 0.01, *** p ≤ 0.001  versus 0 µM MG132; ~ p ≤ 0.05vs 0 pM geldanamycin two-way ANOVA 
followed by Bonferroni post hoc test. 
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Figure 26. Loss of Hsp70/Hsc70 activity abolishes NAC-mediated protection in astrocytes. 
Cortical astrocytes were treated with MG132 or vehicle in the presence or absence of NAC and the 
Hsp70/Hsc70 inhibitors VER155008 (A-C), pifithrin-µ or PES (D-F), and MAL3-101 (G-H). Cell 
viability was measured by blinded counts of Hoechst-stained nuclei. VER155008 and pifithrin-µ 
led to loss of basal viability. Thus, data in panels A and D were expressed as a percentage of the 0 
µM MG132 group in panels B and E to account for the basal viability loss. Representative images 
of Hoechst+ nuclei are illustrated in C, F, and H. Shown are the mean and SEM of 3-5 independent 
experiments. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 versus 0 µM MG132; + p ≤ 0.05, ++ p ≤ 0.01, 
+++ p ≤ 0.001 versus 0 mM NAC; ^ p ≤ 0.05, ^^ p ≤ 0.01, ^^^ p ≤ 0.001 versus 0 µM VER155008, 
pifithrin-µ, or MAL3-101, three-way ANOVA followed by Bonferroni post hoc correction.  
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Figure 27. Inhibition of HO1 activity attenuates protective effects of NAC Cortical astrocytes 
were treated with the indicated concentration of MG132 in the absence and presence of NAC and 
HO1 inhibitor tin protoporphoryrin (SnPPx). A) The relative number of viable astrocytes was 
determined by blinded counts of Hoechst+ nuclei. B) Representative images of Hoechst-stained 
nuclei. *** p ≤ 0.001 versus 0 µM MG132; +++ p ≤ 0.001 versus 0 mM NAC; ^^^ p ≤ 0.001 versus 
0 µM SnPPx three-way ANOVA followed by Bonferroni post hoc correction. 
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NAC attenuates protein-misfolding stress after MG132 treatment 
 As NAC reduced the toxicity of MG132, we tested the hypothesis that it would 
also reduce the increase in ubiquitinated proteins normally seen with proteasome 
inhibitors. Consistent with this hypothesis, NAC abolished the dramatic rise in 
ubiquitinated proteins in response to MG132 treatment, suggesting that proteotoxicity 
was robustly attenuated by NAC (Fig 28A). Previous studies by our group have shown 
that NAC does not reverse MG132-mediated inhibition of proteasome activity in 
neuroblastoma cells (Jiang, et al., 2013). Those studies suggest that NAC does not reduce 
the extent of the original insult, but protects cells downstream from the proteasome. 
Consistent with this notion, NAC did not alter the levels of the proteasomal subunits 
PA28α and PA700 (42 & 46 kDa subunits) in our model (Fig 25B-D). These findings 
support the view that the protective effects of NAC are not related to direct alterations in 
the ubiquitin proteasome system but help mitigate the downstream toxic effects of the 
proteasome inhibtors.  
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Figure 28. NAC decreases ubiquitinated 
proteins in astrocytes after MG132 
treatment. Cortical astrocytes were treated 
with MG132 or vehicle. Lysates were 
collected 24h later and Western blots were 
performed. Representative images are 
shown adjacent to the quantification. A) 
Ubiquitinated proteins, B) PA28α, C) 
PA700 42 kDa subunit, and D) PA700 46 
kDa subunit. All proteins are expressed as a 
fraction of β-actin or α-tubulin levels. 
Infrared images were pseudocolored green 
and red. Shown are the mean and SEM of 3 
independent experiments. * p ≤ 0.05, *** p 
≤ 0.001 versus 0 µM MG132; +++ p ≤ 
0.001 versus 0 mM NAC, two-way 
ANOVA followed by Bonferroni post hoc 
test. 
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3.3 Impact of aging on heat shock proteins in the female rat 
 Aging is the best known risk factor for the development of neurodegenerative 
diseases (Lindsay et al., 2002; Van Den Eeden, et al., 2003). Protein misfolding and 
oxidative stress are thought to accumulate with advancing age (Alavez, Vantipalli, 
Zucker, Klang, & Lithgow, 2011; Attems, Walker, & Jellinger, 2014; Cuanalo-Contreras, 
Mukherjee, & Soto, 2013; David et al., 2010; Driver, Kodavanti, & Mundy, 2000; 
Mecocci et al., 1993; Muller, Lustgarten, Jang, Richardson, & Van Remmen, 2007). 
Therefore, aging may contribute to the pathology associated with neurodegeneration. 
Some heat shock protein defenses are upregulated in neurodegenerative diseases 
(Schipper, et al., 2006; Schipper, et al., 1998; Uryu et al., 2006; Y. Zhang, James, 
Middleton, & Davis, 2005). The effect of aging on several heat shock proteins has mostly 
been measured in male animals (V. Calabrese, et al., 2004; Gupte, et al., 2010; Unno, et 
al., 2000). However, women have a higher incidence of Alzheimer’s disease than men 
(Fratiglioni, et al., 1997) and a lower incidence of Parkinson’s disease (Van Den Eeden, 
et al., 2003), suggesting that there are sex-related differences in vulnerability to 
proteotoxicity. Therefore, an examination of heat shock protein changes in aging females 
is warranted. In the following studies, we used female animals for an extensive 
examination of various heat shock proteins as a function of age, including those heat 
shock proteins highly expressed in astrocytes. Heat shock proteins were examined in 
brain regions known to exhibit pathology in neurodegenerative diseases, such as the 
substantia nigra, striatum and olfactory bulb. We hypothesized that age-related stress 
would be associated with an increase in heat shock proteins, based on previous work in 
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other brain regions (V. Calabrese, et al., 2004; Di Domenico et al., 2010; Dickey, et al., 
2009; Schipper, et al., 2006). 
Aging elicits distinct patterns of heat shock protein changes that vary depending upon 
protein type and brain region 
 A significant increase in Hsp25 was observed in both the striatum and substantia 
nigra from young to old age (Fig 29a and 30a). For example, the oldest animals (19-22 
mo) showed significantly higher Hsp25 levels in the striatum than the youngest animals 
(2-4 mo). Similarly, 19-22 mo old animals expressed higher Hsp25 levels in the 
substantia nigra than 2-4 mo old animals as well as 4-6 mo old animals. Hsp25 levels 
were also higher in the substantia nigra in 19-22 and 16-19 mo old animals than 8-9 mo 
old animals. Hsp25 was elevated in the olfactory bulb after 4 months of age relative to 
the 2-4 month old animals (Fig 32A).  
Next we measured Hsp60 and Hsp70 levels as a function of age. In the striatum, 
19-22 mo old animals expressed higher Hsp60 protein levels than 2-4, 8-9, and 16-19 mo 
old animals (Fig 29e). Middle (8-9 mo) and old (19-22 mo) animals exhibited higher 
Hsp70 levels in the olfactory bulb compared to the youngest animals (2-4 mo) (Fig 32C). 
These findings support the hypothesis that age-related stress increases some heat shock 
protein defenses in a compensatory fashion. 
Proteins tagged specifically for proteasome degradation contain ubiquitin that is 
linked through lysine 48 (K48-linked ubiquitin) (Sadowski & Sarcevic, 2010). In the 
striatum, K48-linked ubiquitin was increased from 4-6 mo of age to 16-19 mo of age (Fig 
29j). These findings are consistent with the view that there is an age-related decline in the 
efficiency of the ubiquitin proteasome system. 
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 In our model, some heat shock proteins exhibited a biphasic response to aging, in 
that there was a rise in heat shock proteins that was reversed with increasing age. For 
example, in the striatum, HO1 protein levels were higher in 8-9 mo old animals relative 
to 2-4 mo old animals (Fig 29b). However, HO1 levels were then decreased in the 16-19 
and 19-22 mo old animals. A biphasic effect was also observed in Hsp60 levels in the 
substantia nigra (Fig 30e) and Hsp40 levels in the striatum (Fig 29c). Middle-aged (8-9 
mo) animals preserved GRP78 expression, whereas 4-6 and 16-22 mo old animals 
exhibited lower GRP78 levels. The increase in heat shock protein defenses in middle-
aged animals may reverse early signs of proteotoxicity but these responses appear to fail 
in the oldest groups. 
Some heat shock protein defenses were also observed to decrease with advancing 
age. For example, Hsc70 was decreased in old age in the striatum and olfactory bulb (Fig 
29f and 32D). Further, HO1 protein levels were decreased from 2-4 to 16-19 months of 
age in the substantia nigra (Fig 30b). The co-chaperone Hip was lower in 4-6 and 19-22 
month old animals relative to young 2-4 month old animals (Fig 29d). The decrease in 
Hip observed in 4-6 month old animals may be related to developmental changes whereas 
lower Hip levels in the oldest animals may be suggestive of age-related declines in some 
co-chaperone defenses. 
Some heat shock proteins were not affected by aging in the striatum, substantia 
nigra, and olfactory bulb. For example, striatal levels of GRP78, pan-ubiquitinated 
proteins, and Hsp90 remained unaffected (Figure 29). No significant changes in GRP78, 
pan-ubiquitinated proteins, Hsp90, Hsp40, Hip, Hsc70, and K48-linked ubiquitin were 
observed in the substantia nigra (Figure 30). Furthermore, CHIP, HO1, Hsp90, Hip, Hop, 
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Hsp60, and mitochondrial Hsp70 (mtHsp70) were not significantly altered by aging in 
the olfactory bulb (Fig 33), Therefore, several heat shock proteins are not upregulated 
with aging and may require higher levels of proteotoxic stress before a response is 
elicited. 
 As Hsp25 was shown to be higher with aging in both the substantia nigra and 
striatum, we suspected that Hsp25 may be present in the dopaminergic neurons that 
comprise the nigrostriatal pathway. As expected, a confocal analysis revealed that Hsp25 
colocalized with tyrosine hydroxylase staining in young, female rats (Fig 31a-c). 
Tyrosine hydroxylase is the rate limiting enzyme for dopamine synthesis and can be used 
as a marker for dopaminergic nigral neurons (Pickel, Joh, Field, Becker, & Reis, 1975). 
Our findings therefore, suggest that Hsp25 is expressed in dopaminergic neurons. Not 
surprisingly, Hsp25 was also expressed in cells lacking tyrosine hydroxylase staining, as 
this protein is known to be ubiquitous and expressed heavily in glia. Age-related 
increases in Hsp25 in the midbrain may help mitigate age-related proteotoxicity in 
dopaminergic neurons as well as other cell types such as astrocytes. Other heat shock 
proteins (HO1 and Hsp60) were also examined using dual-immunofluorescence. 
However, levels of HO1 and Hsp60 in the substantia nigra were below the limits of 
immunohistochemical detection. In order avoid false positive conclusions from antibody 
cross-reactivity, multiple control experiments were conducted. First, tissue sections were 
incubated with one primary antibody (Hsp25 or tyrosine hydroxylase) only, followed by 
exposure to both secondary antibodies. For example, Figure 31d-f illustrates nigral 
staining with mouse antibodies raised against tyrosine hydroxylase antibodies followed 
by exposure to secondary antibodies raised against both mouse and rabbit IgG molecules. 
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The lack of staining in the red channel shows that the anti-rabbit secondary antibodies are 
not cross-reacting inappropriately with the mouse primary antibodies, as we have on 
occasion observed for various secondary antibodies. The lack of signal in the red channel 
also shows clearly that the green tyrosine hydroxylase signal is not bleeding through to 
the red channel during the microscopy. Second, we also ensured that signal was lost when 
the tissue was incubated in no primary antibodies followed by both secondary antibodies.   
In summary, some heat shock proteins were increased with aging in female 
animals as was originally hypothesized. However, reductions and biphasic changes in 
heat shock protein changes were also observed. The changes were highly dependent upon 
the brain region examined, which is not surprising given the heterogeneity of the central 
nervous system 
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Figure 29. Impact of aging on heat shock proteins and ubiquitin-
conjugated proteins in the striatum (caudoputamen). Whole tissue lysates 
of striatal tissue from female Sprague-Dawley rats were probed by Western 
blots for the indicated proteins. GAPDH, α-tubulin, or β-actin was used as a 
protein loading control. * p  0.05 versus 2-4 month old, + p  0.05 versus 4-6 
month old, ~ p  0.05 versus 8-9 month old, ^ p  0.05 versus 16-19 month 
old. Reprinted from “Impact of aging on heat shock protein expression in the 
substantia nigra and striatum of the female rat,” by A. M. Gleixner, 2014, Cell 
Tissue Research, 357, 43-54. Copyright [2014] by A.M Gleixner. Reprinted 
with permission. 
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Figure 30. Impact of aging on heat shock proteins and ubiquitin-conjugated 
proteins in the substantia nigra. Whole tissue lysates of substantia nigra tissue 
from female Sprague-Dawley rats were probed by Western blots for the indicated 
proteins. GAPDH, α-tubulin, or β-actin was used as a protein loading control. * p  
0.05 versus 2-4 month old, + p  0.05 versus 4-6 month old, ~ p  0.05 versus 8-9 
month old, ^ p  0.05 versus 16-19 month old. Reprinted from “Impact of aging on 
heat shock protein expression in the substantia nigra and striatum of the female rat,” 
by A. M. Gleixner, 2014, Cell Tissue Research, 357, 43-54. Copyright [2014] by 
A.M Gleixner. Reprinted with permission. 
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Figure 31. Hsp25 expression in the substantia nigra. Confocal analysis of Hsp25 (red) and 
TH (green) immunostaining in the substantia nigra, pars compacta of a young female rat (top 
panels). Examples of dual-labeled neurons are indicated by white arrows. The dual-labeled 
neurons do not appear yellow in the merged image on the right because the Hsp25 signal was 
weak and the images are not overly manipulated. The bottom panels show an adjacent 
midbrain section that was only incubated in primary antibodies against TH, followed by 
exposure to the same secondary antibody solutions as in the top panels. Reprinted from 
“Impact of aging on heat shock protein expression in the substantia nigra and striatum of the 
female rat,” by A. M. Gleixner, 2014, Cell Tissue Research, 357, 43-54. Copyright [2014] by 
A.M Gleixner. Reprinted with permission. 
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Figure 32. Impact of aging on Hsps and co-chaperones in the olfactory bulb of the female 
rat. (A-E) Infrared Western immunoblots are shown for the indicated Hsps and co-chaperones. 
Olfactory bulb tissue was harvested from female rats at 2.0-3.9 months, 4.0-6.0 months, 8.0-9.0 
months, 16.0-18.9 months, and 19.0-22.0 months of age. GAPDH, α-tubulin, or β-actin was used 
as a protein loading control, depending on the species of the primary antibodies and the expected 
molecular weights. n = 3-6 rats per group. * p ≤ 0.05, ** p ≤ 0.01,  versus 2-4 month old, + p ≤ 
0.05, ++ p ≤ 0.01 versus 4-6 month old, ~ p ≤ 0.05, ~~ p ≤ 0.01  versus 8-9 month old, LSD post 
hoc following one-way ANOVA. Reprinted from “Heat shock protein responses to aging and 
proteotoxicity in the olfactory bulb,” by T.S. Crum, 2014, Journal of Neurochemistry, 133, 780-
794. Copyright [2014] by T.S.Crum. Reprinted with permission. 
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Figure 33. Impact of aging on Hsps and co-chaperones in the olfactory bulb of the 
female rat. (A-G) Infrared Western immunoblots are shown for the indicated Hsps and 
co-chaperones. Olfactory bulb tissue was harvested from female rats at 2.0-3.9 months, 
4.0-6.0 months, 8.0-9.0 months, 16.0-18.9 months, and 19.0-22.0 months of age. GAPDH, 
α-tubulin, or β-actin was used as a protein loading control, depending on the species of the 
primary antibody and the expected molecular weight. n = 3-6 rats per group. * p ≤ 0.05, ** 
p ≤ 0.01,  versus 2-4 month old, + p ≤ 0.05, ++ p ≤ 0.01 versus 4-6 month old, ~ p ≤ 0.05, 
~~ p ≤ 0.01  versus 8-9 month old, LSD post hoc following one-way ANOVA. 
Reprinted from “Heat shock protein responses to aging and proteotoxicity in the olfactory 
bulb,” by T.S. Crum, 2014, Journal of Neurochemistry, 133, 780-794. Copyright [2014] 
by T.S.Crum. Reprinted with permission. 
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Chapter 4 Discussion 
4.1 Exposure to severe proteotoxic stress elicits tolerance in surviving astrocytes 
 Protein misfolding stress, or proteotoxicity, is known to affect both neurons and 
glia in many neurodegenerative disorders, as evidenced by the appearance of protein 
aggregates in both cell types (Braak et al., 2003; Braak, et al., 2007). Further evidence of 
proteotoxicity in these conditions lies in the loss of protein quality control systems, such 
as inhibition of proteasome activity (Cook & Petrucelli, 2009; Q. Huang & Figueiredo-
Pereira, 2010). However, the impact of proteotoxicity on glial cells is less well defined 
than on neurons. Astrocytes are known to harbor misfolded proteins in both Parkinson’s 
and Alzheimer’s disease and to exhibit signs of activation without loss of cell numbers 
(Korolainen, Auriola, Nyman, Alafuzoff, & Pirttila, 2005; Mythri, et al., 2011; Panter, 
McSwigan, Sheppard, Emory, & Frey, 1985; Schultz, Hubbard, Rub, Braak, & Braak, 
2000). These observations suggest that astrocytes are less vulnerable to proteotoxicity in 
these conditions than neurons. If stressed astrocytes can continue to protect and support 
neurons, the onset and progression of neurodegenerative disorders may be delayed. 
Indeed, the slow and protracted nature of these conditions may be explained by both 
neuronal and glial defense mechanisms that are activated by proteotoxic stress, such as 
those examined in the present series of investigations. 
It is well established that astrocytes can adapt to subtoxic levels of cellular stress, 
a phenomenon known as preconditioning or tolerance (Pang, et al., 2015; Sen, et al., 
2011). For example, many studies have examined astrocytic adaptions to cellular stress at 
levels that do not elicit any cell death (Chu, Beart, & Jones, 2010; Gao et al., 2014; 
Rajapakse, Kis, Horiguchi, Snipes, & Busija, 2003). Even though astrocytes are known 
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for their ability to adapt to a subtoxic, fluctuating environment, astrocytic adaptations to 
severe cellular stressors are less well understood (Shao & McCarthy, 1994). Therefore, 
we examined astrocytic responses to severe stress, or stress that is lethal to some fraction 
of the cellular population under study. We tested the hypothesis that exposure to severe 
proteotoxicity would render astrocytes less susceptible to subsequent insults. Although 
astrocytes are not reduced in numbers in neurodegenerative disorders, it was essential to 
significantly decrease astrocyte viability in our studies in order to answer this question. 
We therefore applied lethal concentrations of proteasome inhibitors such as MG132 and 
lactacystin and discovered that cells that managed to survive the first toxic exposure 
exhibited no additional cell death in response to the second exposure to the same toxin. 
These findings demonstrate that severely stressed astrocytes are not necessarily 
weakened. On the contrary, those that survive are more resistant than naïve cells to toxic 
challenges. This is the first study to reveal that astrocytes can adapt to proteotoxic stress 
at concentrations that are high enough to kill a significant population of cells. In contrast 
to these adaptive glial responses, many studies have shown that neurons are weakened by 
exposure to high levels of stress, a phenomenon referred to as the dual hit hypothesis of 
neurodegeneration (Boger, et al., 2010; Sulzer, 2007; Unnithan, et al., 2012; Zhu, et al., 
2007).   
Next we sought to determine the mechanism underlying the protective effects of 
severe stress in astrocytes. For these studies we focused on heat shock proteins and 
glutathione, because heat shock proteins are elevated in astrocytes in Parkinson’s disease 
while glutathione defenses are increased in resistant brain regions such as the frontal 
cortex in this condition (Braak, Del Tredici, Sandmann-Kiel, Rub, & Schultz, 2001; 
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Mythri, et al., 2011; Schipper, et al., 1998). Therefore, we hypothesized that the first hit 
would upregulate heat shock protein and glutathione defenses. As expected, severely 
stressed astrocytes exhibited higher levels of glutathione defenses and several heat shock 
proteins 24h after the first hit (Fig 13 and 14). Similarly, both types of molecules were 
upregulated 24h after the second hit. In order to test whether heat shock protein and 
glutathione defenses mediated the protective effects induced by severe stress, we used the 
pharmacological inhibitors VER155008, SnPPx, and BSO to inhibit Hsp70, Hsp32 
(HO1), and glutathione, respectively. We observed that inhibition of glutathione but not 
Hsp70 or HO1 completely abolished astrocyte stress tolerance (Fig 14 and 17). These 
findings are consistent with the observation that astrocytes are one of the major sources 
of glutathione in the brain (Makar, et al., 1994; Slivka, et al., 1987) and that glutathione 
levels are upregulated in stressed astrocytes in neurodegenerative conditions (Mythri, et 
al., 2011). Although one study demonstrated that heat shock protein 70 can increase 
glutathione redox cycling (Guo, et al., 2007), we did not gather evidence that loss of 
Hsp70 activity altered the ability of stressed astrocytes to resist subsequent proteotoxic 
insults or that it negatively affected glutathione defenses (Fig 14). Instead, there was a 
dramatic increase in glutathione levels in astrocytes treated with VER155008, which may 
help explain why this compound failed to abolish stress resistance in this model.  It 
remains possible that the activity of Hsp70 and HO1 was insufficiently blocked, although 
the reduction in basal survival with the inhibitors does not support this view. We were 
unable to verify the efficacy of VER155008, as the assays for Hsp70 ATPase activity are 
only specific when using pure recombinant Hsp70 and not when examining cellular 
lysates containing multiple types of ATPases other than Hsp70. HO1 activity can be 
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measured in cellular samples because of its unique conversion of toxic heme to bilirubin 
(Drummond & Kappas, 1981; Yoshinaga, et al., 1982). Preliminary data showed that the 
HO1 inhibitor SnPPx decreased enzymatic activity as expected. Another possibility for 
the negative findings with Hsp70 and HO1 inhibitors is compensatory upregulation of 
other heat shock proteins. For example, preliminary data in our lab has shown that Hsp90 
and HO1 levels are elevated in the presence of VER155008. 
As mentioned earlier, glutathione levels are preserved in astrocytes in brain 
regions highly susceptible to Parkinson’s disease (Damier, et al., 1993; Mythri, et al., 
2011). Furthermore, patients with the disease exhibit higher glutathione levels in resilient 
brain regions in comparison to control individuals. Similarly, we observed a stress-
induced increase in glutathione levels that contributed significantly to astrocyte 
resistance. Elimination of xenobiotics by glutathione in the presence of glutathione S-
transferase may also contribute to astrocyte stress tolerance. As mentioned above, 
glutathione S-transferases are enzymes that vary by their N-terminal domain amino acid 
sequence (Mazzetti, et al., 2015). Both glutathione S-transferase μ and π are expressed in 
astrocytes. The 1st MG132 hit increased glutathione S-transferase μ but not glutathione S-
transferase π levels in astrocytes (Fig 14). The absence of glutathione S-transferase μ is 
associated with an earlier age of onset of Parkinson’s disease (Ahmadi et al., 2000). 
Furthermore, glutathione S-transferase μ null genotypes have been associated with a 
higher incidence of Alzheimer’s disease (Piacentini et al., 2012). We also observed a 
stress-induced increase in glutamate cysteine ligase, which plays a role in glutathione 
synthesis. Taken together, these findings suggest that glutathione defenses are essential 
for the protection of astrocytes from severe proteotoxic stress and that the absence of 
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glutathione defenses may increase the likelihood of developing neurodegenerative 
diseases.  
In the present study, we measured viability by performing blinded cell counts of 
Hoechst-stained nuclei and measuring ATP levels. ATP levels are not always in 
proportion to cell numbers and are therefore only interpreted as an indicator of metabolic 
fitness (Posimo, et al., 2014; Titler, et al., 2013). We were unable to use In-Cell Western 
assays for the astrocytic marker GFAP as a third viability assay, because stressed 
astrocytes are known to upregulate GFAP expression (Posimo, et al., 2014; Titler, et al., 
2013). One potential caveat of relying on the Hoechst assay is that it stains all nuclei 
present, including those undergoing apoptosis. The Hoechst-positive nuclei of cells 
undergoing apoptosis are often condensed, fragmented, and/or brightly stained (Abdel 
Wahab, Abdul, Alzubairi, Mohamed Elhassan, & Mohan, 2009; Syed Abdul Rahman, 
Abdul Wahab, & Abd Malek, 2013). Therefore, cells with nuclei under 50 µm2 in area 
were not included in our results. We also investigated the frequency distribution of the 
number of cells with specific nuclear sizes or staining intensities (Fig 11). Median and 
average nuclear sizes were not significantly reduced by the first hit, supporting the view 
that the cells surviving the first hit are indeed viable (Fig 9).  However, average nuclear 
size was slightly decreased after two MG132 insults, suggesting cells were stressed and 
perhaps undergoing apoptosis. Therefore, we performed the TUNEL assay for apoptotic 
cells but discovered that the first MG132 hit did not change the number of TUNEL-
positive cells. The second MG132 hit significantly increased the number of TUNEL-
positive cells in both the control and previously stressed groups, but the total numbers of 
apoptotic cells were low (~10%), suggesting that the vast majority of cells counted after 
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dual hits are indeed viable. It is also important to note here that we were excluding the 
small, dying cells in our viability assays. These findings are entirely consistent with our 
observations that astrocytes survived dual hits even when the interval between the first 
and second hits was increased to 96h and when the interval between the second hit and 
the time of assay was increased to 72h. Had the cells been progressing towards cell death, 
we would not expect to have continued to see protection in the latter studies. 
An examination of the scatterplots of nuclear size versus staining intensity 
suggests that the first hit eliminated cells with small nuclear sizes (50-150 µm2) and 
bright staining intensities (greater than 20 arbitrary units for mean gray value). Indeed, 
cells with small nuclei were more likely to die and wash off the plate at the time of assay 
than cells with larger nuclei, as shown in Figure 11. Small, bright cells may be in the 
process of dying and the MG132 treatment may force them beyond the threshold needed 
to survive. These findings of preferential loss of the smaller cells continue to support the 
hypothesis that MG132 treatment kills the most vulnerable cells and leaves behind the 
more resistant survivors. 
Based on a large body of work, astrocytes are no longer considered a relatively 
uniform population of cells (Hewett, 2009; Y. Zhang & Barres, 2010). In addition to 
regional differences in the properties of astrocytes, astrocytes within a given brain region 
are also structurally and functionally diverse. As argued by Hewett, astrocyte adaptability 
or plasticity contributes to this diversity (cite the man again!!). Early studies had already 
established that astrocytes can be divided into protoplasmic and fibrous groups, which are 
found in gray and white matter, respectively, and exhibit unique morphological 
characteristics (R. H. Miller & Raff, 1984). Astrocyte heterogeneity has been 
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hypothesized to contribute to the differential vulnerability of specific brain regions to 
neurodegenerative disorders. For example, astrocytic glutathione levels are higher in the 
cerebral cortex relative to the substantia nigra in Parkinson’s disease and may explain the 
relative resistance of the former brain region to pathology in this condition. Even within 
the cortex itself, astrocytes exhibit heterogeneity, as they do not uniformly express the 
GFAP and S100β markers (Emsley & Macklis, 2006). This heterogeneity may also be 
reflected in the differential expression of S100β and GFAP in our cortical astrocyte 
cultures; that is, a small number of cells in our cultures only expressed one of these two 
markers. Further evidence of astrocyte heterogeneity in our model is the fundamental 
observation that some astrocytes succumbed to the first hit of MG132 whereas others 
survived this insult and were resistant to further injury. As mentioned above, we observed 
higher vulnerability of astrocytes with small, brightly stained nuclei relative to astrocytes 
with large nuclei. An important goal for future studies would be to determine the unique 
protein profiles of these two distinct groups. One might speculate that the cells with 
larger nuclei have undergone some degree of hypertrophy in vitro, a classic anatomical 
sign of cellular stress, and that they are more likely to engage the enzymes responsible for 
glutathione synthesis and redox cycling, such as glutamate cysteine ligase, glutathione 
reductase, and glutathione peroxidase. Alternatively, cortical astrocytes may naturally 
include both large and small cells and these in vivo features may be retained under in 
vitro culturing conditions. It is worth noting that the astrocytes that survived MG132 
exhibited marked changes in their qualitative appearance, shifting from a stellate shape to 
a bipolar, fusiform, or rounded shape, and expressing higher levels of GFAP (Figure 2). 
Consistent with the view that astrocyte heterogeneity influences their ability to develop 
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stress tolerance, there are reports of differential vulnerabilities of cortical astrocyte 
subpopulations after diffuse traumatic brain injury (Hill, Barbarese, & McIntosh, 1996).  
Previous work suggests that preconditioned astrocytes can still support neuronal 
functions (Sen, et al., 2011). However, it is not clear whether severely stressed astrocyte 
survivors promote or prevent neuronal injury. Some authors have hypothesized the 
reverse, namely that injured astrocytes exacerbate neuronal injury (Fogal, Li, Lobner, 
McCullough, & Hewett, 2007; Gouix, et al., 2014; Jana & Pahan, 2010; Pertusa, Garcia-
Matas, Rodriguez-Farre, Sanfeliu, & Cristofol, 2007). Thus, we sought to determine 
whether stressed astrocyte survivors can protect neurons from proteotoxicity. As 
expected, we observed that severely stressed astrocytes can still protect neighboring 
neurons from proteotoxic injury. Although glutathione was essential for astrocytic stress 
resistance, astrocytes did not rely on glutathione defenses in order to protect neurons 
from proteotoxicity. This finding was unexpected because previous work has shown that 
astrocytes protect neurons by releasing glutathione precursors into the extracellular space 
(Dringen, et al., 2000; Dringen, et al., 1999). Hsp70 is also known to be released from 
astrocytes via exosomes and may decrease proteotoxicity in other models through this 
transcellular process (Taylor, et al., 2007). However, neither inhibition of Hsp70 by 
VER155008 nor glutathione by buthionine sulfoximine attenuated astrocyte-mediated 
neuroprotection in our hands. It is possible that VER155008 may not be as effective in 
the mixed cultures as it is in the neuron-only group simply because there are more cells 
present. However, the stressed astrocyte group with lower cell numbers was more 
protective than the unstressed astrocyte group with higher cell numbers, suggesting that 
greater uptake of inhibitors at lower cell densities did not confound our interpretations. 
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The astrocyte-mediated neuroprotection in our model appeared to be dependent 
upon cell-cell contacts and not a diffusible factor (Fig 20). For example, the 
neuroprotective effects may occur through the diffusion of a small molecule via gap 
junctions (Kozoriz et al., 2010; Nakase, Sohl, Theis, Willecke, & Naus, 2004). 
Alternatively, astrocytes may protect neurons by the uptake of excess glutamate from the 
extracellular space, which would require them to be present at the time of neuronal 
excitotoxicity (Romera et al., 2007). Astrocyte-conditioned medium was concentrated by 
ultra-centrifugation concentrating devices in a preliminary study but showed the same 
results as unconcentrated medium. One possible explanation of these findings is that 
glutathione may diffuse through the concentrating device owing to its small size. If this 
were the case, it would not be delivered to the neurons in the conditioned media exchange 
experiments and we would fail to observe neuroprotection. Alternatively, astrocytes may 
release the diffusible factor immediately following the proteotoxic insult and this factor 
may be degraded in the 24h interval between the MG132 insult and conditioned media 
exchange.  
As mentioned earlier, GFAP is a highly stress-responsive cytoskeletal protein 
thought to be primarily expressed by astrocytes (Eng, Ghirnikar, & Lee, 2000). Changes 
in GFAP expression levels have been attributed to astrocytosis and/or astrocyte 
hypertrophy(Eng, et al., 2000). Mutations in GFAP have been reported in Alexander’s 
disease (Tang, Perng, Wilk, Quinlan, & Goldman, 2010). In this condition, GFAP+ 
protein aggregates may be associated with a toxic gain of astrocyte function (Brenner et 
al., 2001; Messing, Brenner, Feany, Nedergaard, & Goldman, 2012). However, 
attenuation of astrocyte reactivity can also be detrimental to neurological recovery after 
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injury (Liu et al., 2014) and astrocyte cytoskeletal proteins and cellular reactivity are 
thought to be essential for maintaining the astrocyte neurosupportive functions. For 
example, recent studies demonstrate that loss of GFAP increases neuronal loss in the 
brain (Schreiner et al., 2015). Although forced overexpression of GFAP is associated 
with early death in mice (Messing et al., 1998), many studies suggest that physiological 
GFAP upregulation serves to preserve homeostasis. For example, GFAP is essential for 
mitigating traumatic brain injury (Nawashiro, Messing, Azzam, & Brenner, 1998). 
Furthermore, motor neurons in the spinal cord become dysfunctional in the absence of 
GFAP (Schreiner, et al., 2015).  All of these studies are consistent with the findings of the 
present study that reactive astrocytes can continue to support neurons, even under 
conditions of severe injury and after synergistic loss proteasome and Hsp70 chaperone 
functions. 
In conclusion, our studies suggest that astrocytes can adapt to severe 
proteotoxicity, a form of plasticity that may have evolved so that this cell type retains its 
capacity to support neuronal functions. Thus, neurons surrounded by reactive astrocytes 
may be able to survive for longer periods under conditions of proteotoxic stress. It may 
be difficult to generate severely stressed astrocytes in an in vivo model because the 
elimination of even small numbers of astrocytes might incapacitate some neuronal 
functions (Wagner et al., 2006). For example, compromises in astrocytic function may 
contribute to neurodegeneration in Alexander’s disease (Brenner, et al., 2001; Messing, et 
al., 2012). A more targeted approach to eliciting severe proteotoxicity in astrocytes alone 
and one that does not elicit astrocyte death seems warranted.  
Study limitations 
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A number of limitations, in addition to the ones alluded to above, must be 
conceded. First, all pharmacological inhibitors exert nonspecific effects at high 
concentrations. As a result of this concern, we used concentrations that are established in 
the literature, but this does not preclude some off-target effects. One approach to 
blocking heat shock protein activity more specifically in the future might be to use RNA 
interference. However, this method would not circumvent potential compensatory 
responses of other proteins. For example, other heat shock protein family members may 
be upregulated in response to loss of Hsp70 function. It is also important to note that 
MG132 inhibits proteases such as cathepsin A, cathepsin B, and calpain 1 in addition to 
its inhibition of the proteasome, as mentioned in the Introduction (Rivett & Gardner, 
2000). However, the inhibition of these proteases would still contribute to proteotoxic 
effects. For this reason, our model is described as one of loss of protein homeostasis, 
defined as proteotoxicity, rather than selective proteasome inhibition (Morimoto, 2008).  
Second, one might argue that the astrocytes surviving MG132 do not mount any 
active defenses against proteotoxicity but are simply inherently less susceptible to this 
toxin from the very beginning. If the stressed cells were always inherently less 
susceptible, one would expect these cells to have elevated defensive molecules at all 
times relative to untreated cells. If this were indeed the case, one would not expect to 
observe the transient upregulation of Hsp70, HO1, and ubiquitinated proteins after the 
first hit as we did. Furthermore, stressed astrocytes exhibited robust increases in Hsp70, 
HO1, and ubiquitinated proteins after the second hit whether or not they had previously 
been stressed, suggesting that we had not selected for a population of cells that were 
refractory to the effect of the toxin. Finally, if astrocytes had not mounted any defenses in 
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response to MG132, then inhibition of the stress-induced increase in glutathione would 
not have rendered them vulnerable to the toxic effects of dual MG132 hits. In effect, 
glutathione loss unmasks the toxic impact of the second hit. All these data support the 
view that the astrocytes mount active defenses in response to proteotoxicity. 
In our studies, astrocytes were able to attenuate proteotoxicity in neurons despite 
being exposed to high concentrations of MG132 prior to the introduction of neurons (Fig 
18A and 19A). These findings are the first to demonstrate that severely stressed 
astrocytes surviving a lethal insult can still protect neighboring neurons from proteotoxic 
injury although there are greatly reduced in numbers. It is possible that the effects of 
MG132 in the neuron-astrocyte coculture group may be attenuated simply because there 
are greater numbers of cells present to take up the MG132 than the neuron-only cultures. 
However, as mentioned above, this hypothesis is not consistent with the observation that 
astrocytes previously exposed to MG132 (and therefore reduced in numbers) are even 
more protective than the unstressed astrocytes (with greater numbers) in the experiments 
delivering MG132 and VER155008 simultaneously or MG132 and BSO simultaneously 
(Fig 19 and 18). 
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4.2 N-acetyl cysteine protects against protein-misfolding stress in an Hsp70-
dependent manner 
 NAC has been shown to exert some beneficial effects in patients with psychiatric 
and neurodegenerative diseases, perhaps by reducing oxidative stress (Adair, et al., 2001; 
Berk, Copolov, Dean, Lu, Jeavons, Schapkaitz, Anderson-Hunt, Judd, et al., 2008; Berk, 
Copolov, Dean, Lu, Jeavons, Schapkaitz, Anderson-Hunt, & Bush, 2008; M. E. Hoffer, et 
al., 2013). In experimental Parkinson’s disease, NAC has been shown to decrease α-
synuclein+ aggregates, an established sign of protein-misfolding stress, perhaps by raising 
glutathione defenses (Clark et al., 2010). Various doses and delivery methods have been 
used to administer NAC in the clinic. Soldiers experiencing blast injuries were 
administered 4 grams of NAC daily for 4 days after injury followed by 3 grams daily for 
the remainder of the study (M. E. Hoffer, et al., 2013). Rather strikingly, this regimen 
doubled the chances of resolution of neurological symptoms from 42% to 86%. A similar 
oral dose of NAC was given to Alzheimer’s disease patients in capsule form (50 
mg/kg/day) (Adair, et al., 2001). NAC was shown to increase brain glutathione levels in 
Parkinson’s disease patients when delivered at 150 mg/kg by intravenous infusion for one 
hour (Holmay, et al., 2013). However, NAC is thought to have an oral bioavailability of 
only 9.1% (Olsson, Johansson, Gabrielsson, & Bolme, 1988). On the other hand, many 
studies have shown that orally delivered NAC can have protective effects on neurons in 
vivo and increase brain glutathione levels in experimental models of neurological 
disorders, suggesting it crosses the blood-brain barrier in sufficient quantities (Grant, 
Odlaug, & Kim, 2009; R. W. Hurd, Wilder, Helveston, & Uthman, 1996; Lavoie et al., 
2008). Nevertheless, chemical modifications to NAC have been investigated due to 
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perceived poor bioavailability (Giustarini, Milzani, Dalle-Donne, Tsikas, & Rossi, 2012; 
Sunitha et al., 2013). Either way, the effective in vitro concentration (3 mM) used in the 
present investigation likely surpasses concentrations delivered to cells in in vivo studies. 
It is possible that higher concentrations are needed in vitro than in vivo because of high 
basal levels of oxidative stress under in vitro culturing conditions (Halliwell, 2014). 
Further studies are warranted to continue to improve NAC bioavailability.  
NAC has already been shown to decrease cellular stress in astrocytes in 
experimental models of ischemia and pain (Bernabucci et al., 2012; Gabryel, Toborek, & 
Malecki, 2005). As mentioned previously, astrocytes exhibit protein-misfolding stress in 
neurodegenerative diseases (Allen & Barres, 2009; Braak, et al., 2007; Kimelberg & 
Nedergaard, 2010). Because astrocytes help preserve neuronal function, it is important to 
identify therapies that protect astrocytes from protein-misfolding stress in order to 
mitigate loss of neuroprotective features. Our study demonstrates that NAC might be one 
such candidate. Other studies in the Leak lab have shown that NAC can also protect 
cortical neurons and neuroblastoma cells against proteotoxic and oxidative stress, 
supporting the view that the protective effects of NAC are generalizable across multiple 
experimental models (Posimo, et al., 2013; Unnithan, et al., 2012; Unnithan et al., 2014). 
The generalizability across different models improves the chances of success in the 
clinic. 
 As mentioned above, previous studies in the Leak lab have shown that NAC 
protects neuroblastoma cells against MG132 (Jiang, et al., 2013). In those studies, 
MG132 was effective at inhibiting the chymotrypsin-like activity of the proteasome in the 
presence or absence of NAC. Furthermore, in our astrocyte study, expression of 
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proteasomal subunits was not altered by NAC treatment. In contrast, the dramatic 
MG132-mediated rise in ubiquitin-conjugated proteins was abolished by NAC in both 
neuroblastoma cells and astrocytes. Taken together, these findings suggest that NAC 
decreases proteotoxicity through a mechanism independent of direct effects on 
proteasome activity. Had NAC directly reduced the effects of MG132 on the proteasome, 
we would not have been able to conclude that it protects against protein misfolding stress 
because the toxin would simply be less effective in the NAC-treated group. Instead, NAC 
may be reducing the burden of misfolded, ubiquitinated proteins by improving chaperone 
and antioxidant defenses (see below). 
Neurodegenerative diseases are characterized by both protein-misfolding and 
oxidative stress, which propel and propagate each other and amplify the injury. For 
example, proteasome inhibition has been shown to increase oxidative stress (Maharjan, et 
al., 2014). NAC is thought to provide the rate-limiting component in glutathione 
synthesis (E. Hoffer, et al., 1996). However, in our astrocytes, NAC was protective 
independent of glutathione synthesis, as its therapeutic potential was not abolished by 
buthionine sulfoximine. Unexpectedly, NAC attenuated the MG132-mediated rise in 
glutathione. However, NAC has been observed to attenuate stress-induced rises in 
glutathione in other models, demonstrating that our findings are not entirely 
unprecedented (Tchantchou, Graves, Rogers, Ortiz, & Shea, 2005). Although NAC 
attenuated proteotoxicity independent of glutathione synthesis, NAC may nevertheless 
reduce oxidative stress in astrocytes by the direct antioxidant activity of the thiol group 
(Aruoma, et al., 1989). This may prevent oxidative damage to proteins, including Hsp70 
and other chaperones, and as a result, decrease proteotoxicity. Furthermore, if NAC 
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directly reduces oxidative stress, this may explain the mitigation of the stress-induced rise 
in glutathione levels.  
The cysteine of NAC can exist in two isomeric forms: L-cysteine and D-cysteine. 
Both forms of the amino acid can reduce oxidative stress through redox cycling of the 
cysteine sulfhydryl group. L-cysteine but not D-cysteine can be incorporated into 
glutathione. In our studies, both L-cysteine and D-cysteine were shown to protect 
astrocytes against MG132 toxicity, as was observed with NAC. Some amino acids can be 
converted from the D- to L-isoform by D-amino acid oxidase (Friedman & Levin, 2012; 
Sacchi, et al., 2008). Thus, D-cysteine may decrease proteotoxic stress by first being 
converted to L-cysteine followed by incorporation into glutathione. However, inhibition 
of D-amino acid oxidase with sodium benzoate did not alter the protective effect of D-
cysteine in our study (Katane, et al., 2013; Van den Berghe-Snorek & Stankovich, 1985), 
suggesting that the conversion reaction was not significant in our model. Future studies 
are needed to confirm that L-cysteine is directly protective and not protective through 
interconversion to glutathione, perhaps by using buthionine sulfoximine to inhibit 
cysteine incorporation into glutathione. Nevertheless, all the data collected thus far in our 
model are consistent with the view that protection by NAC is not dependent upon 
glutathione synthesis. Thus, we speculate that the robust protection by NAC may depend 
upon the cysteine sulfhydryl group, which is also present in both L-cysteine and D-
cysteine.  
Thiol exchange reactions can facilitate activation of transcription factors such as 
Nrf2 and HSF1 (Dinkova-Kostova, 2012). For example, NAC might be expected to react 
with cysteine residues on Keap1. As a result, Keap1-mediated degradation of Nrf2 would 
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be attenuated, enabling its translocation from the cytoplasm to the nucleus and the 
transcription of genes such as HO1 and HSPA1B, which encodes Hsp70 (Hu, et al., 2006; 
Kwak, et al., 2003; Qi et al., 2013). Similarly, thiol exchange reactions between NAC and 
the cysteine residues in HSF1 might elicit transcription of Hsp70 genes. However, our 
studies showed that NAC attenuated MG132-mediated increases in HO1 and Hsp70 
expression. Contrary to the results observed in astrocytes, other studies in our lab have 
shown that NAC increases Hsp70 in N2a cells (Jiang, et al., 2013) and in cortical neurons 
(unpublished findings). The reasons underlying this discrepancy are still under 
investigation. 
 Although NAC attenuated the MG132-mediated rises in Hsp70 and HO1, we 
investigated whether inhibition of Hsp70 and HO1 activity attenuated NAC-mediated 
protection because changes in protein levels do not always coincide with changes in 
activity. Three pharmacological inhibitors for Hsp70 (VER155008, pifithrin-μ, and 
MAL3-101) with different mechanisms of action and one pharmacological inhibitor of 
HO1 (SnPPx) activity all attenuated astrocytic protection by NAC. These findings 
suggest that Hsp70 and/or HO1 activity is important for NAC-mediated protection. It 
remains possible that NAC preserves Hsp70 or HO1 activity under conditions of 
oxidative stress by direct antioxidant action. For example, NAC may prevent oxidative 
damage to these proteins. Other studies in the Leak lab have also shown that Hsp70 
inhibitors abolish NAC-mediated protection in N2a cells, cortical neurons, and 
hippocampal neurons, suggesting that NAC protects multiple cell types in an Hsp70-
dependent manner. 
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Heat shock proteins such as Hsp70 and HO1 are known to be higher in patients 
with neurodegenerative diseases relative to control subjects, probably because the stimuli 
to induce their expression include proteotoxic and oxidative stress (Schipper, et al., 2006; 
Schipper, et al., 1998; Wu et al., 2004). The upregulation of these heat shock protein 
molecules may be a compensatory response to damage to some fraction of the heat shock 
protein pool, resulting in a loss of negative feedback on heat shock protein gene 
transcription and translation. NAC may protect in part by reducing further damage to heat 
shock proteins and in turn, this may enable more efficient refolding and degradation by 
Hsp70 and superior heme degradation by HO1. Based on the dramatic reduction in 
ubiquitinated proteins and the potential facilitation of Hsp70 refolding activity, NAC is 
expected to slow or halt further accumulation of protein aggregates in patients with 
neurodegenerative conditions.  
As described above, measurements of Hsp70 activity are not feasible in cellular 
lysates because many molecules in these lysates exhibit ATPase activity in addition to 
Hsp70. It is therefore not possible to assess whether NAC protects astrocytes by 
increasing Hsp70 activity in the astrocyte model. To address this gap, one might assess 
the activity of pure, recombinant Hsp70 in the presence of NAC (Z. Lu & Cyr, 1998), 
although such experiments would not establish a definitive mechanism in the astrocyte 
model. Cysteine residues on Hsp70 are susceptible to oxidative damage that might hinder 
ATPase activity (Miyata, et al., 2012). If NAC reverses damage to Hsp70, this would 
suggest that NAC decreases proteotoxicity by preserving normal Hsp70 function.  
 As mentioned above, all pharmacological inhibitors have off-target effects at high 
concentrations. Therefore, multiple pharmacological inhibitors were used to examine the 
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role of Hsp70 activity in NAC-mediated protection against MG132. VER155008 and 
pifithrin-µ are known to inhibit autophagy, but this may occur through inhibition of 
Hsc70 (Budina-Kolomets et al., 2013; Leu, et al., 2011), because Hsc70 escorts proteins 
to the lysosome for autophagic degradation (Arias & Cuervo, 2011). Despite potentially 
nonspecific effects, the overlapping effects of the inhibitors suggest that Hsp70 activity 
loss is indeed responsible for reducing NAC-mediated protection. In other words, it 
would be unlikely that all three inhibitors have the same non-specific effects. 
 In conclusion, protein aggregate buildup may be attenuated by NAC through the 
thiol-mediated prevention of disulfide bond formation (Samuni, Goldstein, Dean, & Berk, 
2013). The accumulation of protein aggregates may also be reversed in the presence of 
Hsp70 (Chittoor-Vinod, Lee, Judge, & Notterpek, 2015). Our studies reveal that NAC-
mediated protection of astrocytes is dependent upon Hsp70 activity. Preservation of 
astrocyte function by NAC would be expected to contribute to neuronal homeostasis and 
slow down the neurodegenerative process.  
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4.3 Natural aging elicits changes in heat shock proteins in multiple brain regions  
 Heat shock proteins are important for restoring protein homeostasis under 
conditions of proteotoxic stress. Perez and colleagues found that longevity is determined 
in part by protein stability and resistance to oxidative damage (Perez et al., 2009). Some 
studies have shown that heat shock protein defenses wane with advancing age while 
others have shown age-related increases in heat shock proteins (Alladi, et al., 2010; 
Dickey, et al., 2009; Ewing & Maines, 2006; Gupte, et al., 2010; C. K. Lee, Weindruch, 
& Prolla, 2000; Paz Gavilan, et al., 2006). The impact of aging in the substantia nigra and 
striatum on heat shock proteins has been previously examined (V. Calabrese, et al., 2004; 
Ewing & Maines, 2006; Gupte, et al., 2010; Unno, et al., 2000). However, all of these 
animal studies were conducted in males. Thus, the present study is the first to assess the 
relationship between natural aging and heat shock protein expression in the substantia 
nigra, striatum, and olfactory bulb in female rats.  
 In this study, some heat shock proteins, such as Hsp25 and Hsp70, were observed 
to increase with advancing age. These increases may be the result of compensatory 
responses to age-related proteotoxic and oxidative stress. For example, cells may elevate 
heat shock protein levels to reverse or slow the detrimental effects of age-related loss of 
proteasome activity (Martinez-Vicente, et al., 2005). As misfolded proteins are 
ubiquinated prior to proteasomal degradation, proteotoxic stress was measured by 
assessing ubiquitin-conjugated proteins in our studies. The statistical trends towards age-
related increases in pan ubiquitin-conjugated proteins in the substantia nigra and striatum 
are suggestive of an increase in proteotoxic stress. Furthermore, K48-linked ubiquitin in 
the striatum was higher in older animals in comparison to 4-6 month old rats. However, 
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no significant increases in K48-linked ubiquitin levels were observed in the substantia 
nigra. K48-linked ubiquitin is a more direct assessment of proteotoxicity than pan 
ubiquitin as some molecules are ubiquitinated without being targeted to the proteasome. 
For example, linkages between ubiquitin molecules at lysine 63 signal endocytosis, 
kinase activation, and DNA damage, and not proteasomal degradation (Sadowski & 
Sarcevic, 2010). Measuring proteasome activity would be an important goal for future 
aging studies in our model.  
The female Sprague Dawley rat has been shown to have a lifespan ranging from 
193-1100 days (Davis, Stevenson, & Busch, 1956). The oldest animals in our study were 
sacrificed at 22 months because some began to exhibit poor health and die. Even older 
animals might have exhibited a more robust increase in proteotoxic stress. In future 
studies we would need to house a large number of animals to account for high rates of 
spontaneous death after two years of age. 
A thorough understanding of age-related disruptions to proteostasis and the 
response of heat shock proteins to these changes is important for the identification of new 
therapeutic targets. However, some authors have argued that aging animal models have 
poor predictive validity. Sengupta and colleagues reviewed factors such as teeth, sexual 
development, and musculoskeletal systems as important for relating rat age to human age 
(Sengupta, 2013). Based upon these factors, the authors suggested that rats encounter 
developmental stages at different rates than humans and therefore, caution must be 
exerted when correlating rat to human ages. In other words, changes in heat shock protein 
expression at specific rat ages may be difficult to extrapolate to human developmental 
stages.   
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Depending upon the brain region examined, some heat shock protein defenses, 
such as Hsp40 and Hsc70 were observed to wane with advancing age. These effects 
would be expected to contribute to a progressive accumulation of protein aggregates. 
Despite declines in expression of these heat shock proteins, age-related increases in 
ubiquitinated proteins were small in size, suggesting that other heat shock proteins may 
have compensated for deficits in these proteins. Thus, the overall severity of age-related 
proteotoxicity is likely to be the result of the concerted efforts of multiple heat shock 
protein defenses and proteasomal and autophagic clearance mechanisms. 
In our work, we have shown that the relationships between aging and heat shock 
proteins are highly dependent upon brain region. For example, Hsp25 increased in the 
female rat olfactory bulb, striatum, and substantia nigra with aging. For example, Hsp25 
was higher in 4-22 month animals in comparison to the youngest animals in the olfactory 
bulb. This may be suggestive of developmental changes in Hsp25 expression. As both the 
striatum and the nigra exhibited a rise in Hsp25, we hypothesized that Hsp25 may be 
present within the dopaminergic neurons that form the nigrostriatal pathway. Confocal 
analyses confirmed that Hsp25 was present in tyrosine hydroxylase+ dopaminergic 
neurons of the substantia nigra. In addition, Hsp25 was also present in cells not 
expressing tyrosine hydroxylase, as one might expect given the ubiquitous nature of this 
heat shock protein. If the number of dopaminergic neurons decrease with aging as has 
been reported in some models, the rise in Hsp25 observed in the present study may be 
attributed to Hsp25 expression within other cell types (Gibb & Lees, 1991).  
As mentioned above, the confocal analysis suggests that Hsp25 is expressed in 
both dopaminergic and non-dopaminergic cells in the ventral mesencephalon. Some of 
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the Hsp25-expressing non-dopaminergic cells are expected to be glial in nature, as Hsp25 
is known to be highly expressed in astrocytes (Chen & Swanson, 2003; Stetler, Gao, 
Signore, Cao, & Chen, 2009). Hsp25 expression has been shown to be increased in 
various models of neurological disorders and with natural aging (Crum et al., 2015a; 
Gleixner, et al., 2014; Gupte, et al., 2010; Strey et al., 2004). For example, Hsp25 
expression within glial cells is increased in transgenic models of amyotrophic lateral 
sclerosis (Wang, Martin, Gonzales, Borchelt, & Lee, 2008). Future studies to investigate 
the differential impact of aging and proteotoxicity on Hsp25 levels in glial and neurons 
are warranted, as they may provide insight into the differential susceptibility of various 
cell types to proteotoxicity.  
Several authors have speculated that the olfactory bulb is especially vulnerable to 
protein inclusions in neurological disorders because of greater exposure to environmental 
pathogens than deeper brain regions. For example, α-synuclein+ aggregates appear in the 
olfactory bulb long before they emerge in the ventral mesencephalon in Parkinson’s 
disease (Hawkes, Del Tredici, & Braak, 2009). Based on these histological observations, 
one would expect to see heat shock protein changes in the olfactory bulb before similar 
changes appear within the nigrostriatal pathway in Parkinson’s patients. Future studies to 
test this hypothesis might help correlate the emergence of Lewy pathology with stress 
responses in heat shock proteins. Such findings would also be consistent with histological 
studies showing that Lewy bodies contain high levels of Hsp70 molecules (Shin, 
Klucken, Patterson, Hyman, & McLean, 2005). 
Some heat shock protein responses to aging differed between the substantia nigra 
and striatum. For example, HO1 was decreased with aging in the substantia nigra, 
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whereas a biphasic response in HO1 levels was observed in the striatum. The discrepancy 
between the nigral and striatal HO1 changes may suggest that HO1 is present in cells 
other than dopaminergic neurons of the nigrostriatal pathway. Despite our repeated 
efforts to address this question, multiple antibodies against HO1 were ineffective by 
immunohistochemistry and only worked in Western blot analyses.  
 An age-related decline in Hsc70 was observed in both the olfactory bulb and the 
striatum. As mentioned above, Hsc70 recognizes proteins with the KFERQ-like sequence 
and escorts them to the lysosome for chaperone-mediated autophagic degradation (Boya, 
Reggiori, & Codogno, 2013). A loss of Hsc70 expression with aging would therefore be 
expected to contribute to autophagic stress. As expression of the membrane protein 
LAMP2A is thought to reflect levels of chaperone mediated autophagy (Boya, et al., 
2013), future studies to measure LAMP2A protein levels to assess age-related changes in 
autophagy in the olfactory bulb and striatum might be valuable. 
For our in vivo studies, we used female rats. Advancing age leads to cessation of 
estrous cycling in female rats (Sone et al., 2007). It is possible that fluctuations in the 
estrous cycle may have contributed to some of the high variability observed in some of 
the heat proteins. Estrous cycling is already known to have an impact on Hsp25 
expression (Steffl, Telgen, Schweiger, & Amselgruber, 2010). Similarly, Hsp70 
expression levels also fluctuate with the estrous cycle (Muthukumar et al., 2014).  In 
order to reduce variability, vaginal smears to determine the phase of the estrous cycle 
might be helpful. However, if the data were stratified according to the estrous cycle, we 
would need many more animals in each group. 
129 
 
In conclusion, aging is the most important risk factor for the development of 
neurodegenerative diseases, all of which are characterized by loss of proteostasis and 
changes in heat shock proteins (Alladi, et al., 2010; Dickey, et al., 2009; Ewing & 
Maines, 2006; Gupte, et al., 2010; Keller, Hanni, & Markesbery, 2000b; Keller, Huang, 
et al., 2000; C. K. Lee, et al., 2000; Martinez-Vicente, et al., 2005; Paz Gavilan, et al., 
2006; Van Den Eeden, et al., 2003). However, not all aged individuals suffer from 
neurodegenerative diseases and it is therefore important to understand heat shock protein 
defenses in the absence of pathological changes. It is worth noting that our study of the 
relationship between normal aging and heat shock proteins was only correlative and did 
not establish any causal links. In order to assess the importance of the observed changes 
in heat shock proteins, knockout, knockdown, or antagonism experiments would be 
necessary. Alternatively, the proteins in question might be overexpressed to determine if 
this increases lifespan and protects against insults in experimental models. The 
information garnered in the present study would be useful in guiding such future 
investigations. 
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